<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38783367</article-id><article-id pub-id-type="pmc">PMC11118550</article-id>
<article-id pub-id-type="publisher-id">4903</article-id><article-id pub-id-type="doi">10.1186/s13054-024-04903-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Dyspnea is severe and associated with a higher intubation rate in de novo acute hypoxemic respiratory failure</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Demoule</surname><given-names>Alexandre</given-names></name><address><email>alexandre.demoule@aphp.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Baptiste</surname><given-names>Amandine</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Thille</surname><given-names>Arnaud W.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Similowski</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Ragot</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Prat</surname><given-names>Gw&#x000e9;nael</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Mercat</surname><given-names>Alain</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Girault</surname><given-names>Christophe</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Carteaux</surname><given-names>Guillaume</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Boulain</surname><given-names>Thierry</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Perbet</surname><given-names>S&#x000e9;bastien</given-names></name><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Decav&#x000e8;le</surname><given-names>Maxens</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Belin</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Frat</surname><given-names>Jean-Pierre</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><collab>from the REVA Network (Research Network in Mechanical Ventilation)</collab></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02en5vm52</institution-id><institution-id institution-id-type="GRID">grid.462844.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2308 1657</institution-id><institution>INSERM, UMRS1158 Neurophysiologie Respiratoire Exp&#x000e9;rimentale et Clinique, </institution><institution>Sorbonne Universit&#x000e9;, </institution></institution-wrap>75005 Paris, France </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02mh9a093</institution-id><institution-id institution-id-type="GRID">grid.411439.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2150 9058</institution-id><institution>Groupe Hospitalier Universitaire APHP-Sorbonne Universit&#x000e9;, Site Piti&#x000e9;-Salp&#x000ea;tri&#x000e8;re, Service de M&#x000e9;decine Intensive et R&#x000e9;animation (D&#x000e9;partement R3S), H&#x000f4;pital Universitaire Piti&#x000e9;-Salp&#x000ea;tri&#x000e8;re, </institution><institution>AP-HP, </institution></institution-wrap>47-83 Boulevard de L&#x02019;H&#x000f4;pital, 75651 Paris Cedex 13, France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00pg5jh14</institution-id><institution-id institution-id-type="GRID">grid.50550.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2175 4109</institution-id><institution>Groupe Hospitalier Universitaire APHP-Sorbonne Universit&#x000e9;, Site Piti&#x000e9;-Salp&#x000ea;tri&#x000e8;re, Unit&#x000e9; de Recherche Clinique, </institution><institution>AP-HP, </institution></institution-wrap>Paris, France </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/029s6hd13</institution-id><institution-id institution-id-type="GRID">grid.411162.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 9336 4276</institution-id><institution>M&#x000e9;decine Intensive R&#x000e9;animation, </institution><institution>Centre Hospitalier Universitaire de Poitiers, </institution></institution-wrap>Poitiers, France </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04xhy8q59</institution-id><institution-id institution-id-type="GRID">grid.11166.31</institution-id><institution-id institution-id-type="ISNI">0000 0001 2160 6368</institution-id><institution>Centre d&#x02019;Investigation Clinique 1402 ALIVE, </institution><institution>Universit&#x000e9; de Poitiers, </institution></institution-wrap>Poitiers, France </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00pg5jh14</institution-id><institution-id institution-id-type="GRID">grid.50550.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2175 4109</institution-id><institution>Groupe Hospitalier Universitaire APHP-Sorbonne Universit&#x000e9;, Site Piti&#x000e9;-Salp&#x000ea;tri&#x000e8;re, D&#x000e9;partement R3S, </institution><institution>AP-HP, </institution></institution-wrap>75013 Paris, France </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03evbwn87</institution-id><institution-id institution-id-type="GRID">grid.411766.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0472 3249</institution-id><institution>Service de M&#x000e9;decine Intensive et R&#x000e9;animation, </institution><institution>CHU de Brest, </institution></institution-wrap>Brest, France </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0377z4z10</institution-id><institution-id institution-id-type="GRID">grid.31151.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0593 7185</institution-id><institution>Service de R&#x000e9;animation m&#x000e9;dicale et M&#x000e9;decine Hyperbare, </institution><institution>Centre Hospitalier R&#x000e9;gional Universitaire, </institution></institution-wrap>Angers, France </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01k40cz91</institution-id><institution-id institution-id-type="GRID">grid.460771.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1785 9671</institution-id><institution>UNIROUEN, UR 3830, Medical Intensive Care Unit, Rouen University Hospital, </institution><institution>Normandie University, </institution></institution-wrap>Rouen, France </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00pg5jh14</institution-id><institution-id institution-id-type="GRID">grid.50550.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2175 4109</institution-id><institution>H&#x000f4;pitaux Universitaires Henri Mondor, Service de M&#x000e9;decine Intensive R&#x000e9;animation, Universit&#x000e9; Paris Est Cr&#x000e9;teil, Groupe de Recherche Clinique CARMAS, </institution><institution>AP-HP, </institution></institution-wrap>Cr&#x000e9;teil, France </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/014zrew76</institution-id><institution-id institution-id-type="GRID">grid.112485.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0217 6921</institution-id><institution>M&#x000e9;decine Intensive R&#x000e9;animation, </institution><institution>Centre Hospitalier Universitaire d&#x02019;Orl&#x000e9;ans, </institution></institution-wrap>Orl&#x000e9;ans, France </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02tcf7a68</institution-id><institution-id institution-id-type="GRID">grid.411163.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0639 4151</institution-id><institution>R&#x000e9;animation M&#x000e9;dico-Chirurgicale, </institution><institution>CHU de Clermont-Ferrand, </institution></institution-wrap>Clermont-Ferrand, France </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01a8ajp46</institution-id><institution-id institution-id-type="GRID">grid.494717.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2173 2882</institution-id><institution>GReD, UMR/CNRS 6293, INSERM U1103, </institution><institution>Universit&#x000e9; Clermont Auvergne, </institution></institution-wrap>Clermont-Ferrand, France </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02vjkv261</institution-id><institution-id institution-id-type="GRID">grid.7429.8</institution-id><institution-id institution-id-type="ISNI">0000000121866389</institution-id><institution>Site Piti&#x000e9;-Salp&#x000ea;tri&#x000e8;re, D&#x000e9;partement de Sant&#x000e9; Publique, </institution><institution>INSERM, Institut Pierre Louis d&#x02019;Epid&#x000e9;miologie Et de Sant&#x000e9; Publique, AP-HP, APHP-Sorbonne Universit&#x000e9;, </institution></institution-wrap>Paris, France </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>28</volume><elocation-id>174</elocation-id><history><date date-type="received"><day>16</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>5</day><month>4</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024, corrected publication 2025</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Dyspnea is a key symptom of de novo acute hypoxemic respiratory failure. This study explores dyspnea and its association with intubation and mortality in this population.</p></sec><sec><title>Methods</title><p id="Par2">This was a secondary analysis of a multicenter, randomized, controlled trial. Dyspnea was quantified by a visual analog scale (dyspnea-VAS) from zero to 100&#x000a0;mm. Dyspnea was measured in 259 of the 310 patients included. Factors associated with intubation were assessed with a competing risks model taking into account ICU discharge. The Cox model was used to evaluate factors associated with 90-day mortality.</p></sec><sec><title>Results</title><p id="Par3">At baseline (randomization in the parent trial), median dyspnea-VAS was 46 (interquartile range, 16&#x02013;65) mm and was&#x02009;&#x02265;&#x02009;40&#x000a0;mm in 146 patients (56%). The intubation rate was 45%. Baseline variables independently associated with intubation were moderate (dyspnea-VAS 40&#x02013;64&#x000a0;mm) and severe (dyspnea-VAS&#x02009;&#x02265;&#x02009;65&#x000a0;mm) dyspnea at baseline (sHR 1.96 and 2.61, <italic>p</italic>&#x02009;=&#x02009;0.023), systolic arterial pressure (sHR 2.56, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), heart rate (sHR 1.94, <italic>p</italic>&#x02009;=&#x02009;0.02) and PaO<sub>2</sub>/FiO<sub>2</sub> (sHR 0.34, <italic>p</italic>&#x02009;=&#x02009;0.028). 90-day mortality was 20%. The cumulative probability of survival was lower in patients with baseline dyspnea-VAS&#x02009;&#x02265;&#x02009;40&#x000a0;mm (logrank test, <italic>p</italic>&#x02009;=&#x02009;0.049). Variables independently associated with mortality were SAPS 2&#x02009;&#x02265;&#x02009;25 (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), moderate-to-severe dyspnea at baseline (<italic>p</italic>&#x02009;=&#x02009;0.073), PaO<sub>2</sub>/FiO<sub>2</sub> (<italic>p</italic>&#x02009;=&#x02009;0.118), and treatment arm (<italic>p</italic>&#x02009;=&#x02009;0.046).</p></sec><sec><title>Conclusions</title><p id="Par4">In patients admitted to the ICU for de novo acute hypoxemic respiratory failure, dyspnea is associated with a higher risk of intubation and with a higher mortality.</p><p id="Par5"><bold>Trial registration</bold>: clinicaltrials.gov Identifier # NCT 01320384.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13054-024-04903-5.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Dyspnea</kwd><kwd>High-flow oxygen therapy</kwd><kwd>Mortality</kwd><kwd>Intubation</kwd><kwd>Acute respiratory failure</kwd></kwd-group><funding-group><award-group><funding-source><institution>This work was supported by a grant from the French Ministry of Health</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par16">Acute respiratory failure (ARF) results from an imbalance between the load and the capacity of the respiratory system. Noninvasive respiratory support such as high flow oxygen therapy (HFOT) and noninvasive ventilation (NIV) may prevent intubation by reducing load capacity imbalance and hence signs of respiratory distress [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Early prediction of the need for intubation in patients with de novo hypoxemic ARF remains challenging. Many factors supposed to predict intubation, such as severe hypoxemia, shock or coma, are themselves actually intubation criteria [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. The best prediction accuracy of the ratio of respiratory-rate-oxygenation index is after 12&#x000a0;h of HFOT [<xref ref-type="bibr" rid="CR8">8</xref>]. Tidal volume is also a good predictor of intubation, but only in patients receiving NIV [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par17">Dyspnea, the abnormal and distressing awareness of breathing, is a key symptom of ARF [<xref ref-type="bibr" rid="CR11">11</xref>]. As opposed to physical signs of respiratory distress such as tachypnea and labored breathing, dyspnea is a symptom, which places a very strong emphasis on self-reporting [<xref ref-type="bibr" rid="CR11">11</xref>]. Because it parallels respiratory drive, dyspnea is a marker of load capacity imbalance [<xref ref-type="bibr" rid="CR12">12</xref>]. As such, dyspnea could help to predict intubation. Reports on dyspnea as a predictor of intubation are scarce. In patients receiving NIV for ARF of a mixed nature, dyspnea was associated with adverse outcomes, including NIV failure [<xref ref-type="bibr" rid="CR13">13</xref>]. Similar results were observed in COVID-19 patients [<xref ref-type="bibr" rid="CR14">14</xref>]. Of note, dyspnea was among intubation criteria of only one of the large randomized controlled trials published in the last decade and in which intubation was the primary or a major secondary outcome [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. The reason why dyspnea has been so little studied is unclear.</p><p id="Par18">Here, we performed a post hoc analysis of a large scale multicenter, randomized controlled trial in which dyspnea was measured [<xref ref-type="bibr" rid="CR1">1</xref>]. Our first objective was to quantify the prevalence and intensity of dyspnea in non-intubated patients receiving noninvasive respiratory support (either standard oxygen, HFOT or NIV delivered by an ICU ventilator) for de novo hypoxemic ARF and to examine factors associated with dyspnea. Our second objective was to investigate the association between dyspnea and intubation. Finally, we examined the association between dyspnea and mortality. Our hypotheses were that dyspnea was frequent and severe in this population, and that a more intense dyspnea was associated with a higher risk of intubation and mortality.</p></sec><sec id="Sec2"><title>Patients and methods</title><sec id="Sec3"><title>Study population and design</title><p id="Par19">We performed a post hoc analysis of a randomized, controlled trial (NCT 01320384, registered on 22 March 2011) conducted in 23 centers in France and Belgium [<xref ref-type="bibr" rid="CR1">1</xref>]. In this study, 310 patients admitted to ICU with ARF were randomly assigned to receive a treatment by standard oxygen, HFOT or NIV delivered by an ICU ventilator. All patients had a respiratory rate&#x02009;&#x0003e;&#x02009;25 breaths/min, a ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO<sub>2</sub>/FiO<sub>2</sub>)&#x02009;&#x02264;&#x02009;300&#x000a0;mm Hg and a PaCO<sub>2</sub>&#x02009;&#x02264;&#x02009;45&#x000a0;mmHg. The main exclusion criteria were severe neutropenia, acute-on-chronic respiratory failure, cardiogenic pulmonary edema, shock or altered consciousness. The original parent trial was approved by ethics committees at Centre Hospitalier Universitaire de Poitiers for French study sites (n. 10.11.28, 28 December 2010) and at Cliniques Universitaires Saint-Luc, Brussels for the site in Belgium (n. 10.07.12, 3 May 2011). Written informed consent was obtained from all the patients, their next of kin or another surrogate decision-maker as appropriate. According to French law, this post hoc analysis of the original study did not need additional ethics approval as no more data were collected for this analysis. Procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as most recently amended. Two other post hoc analyses of this study have been already published [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="Sec4"><title>Data collection and predetermined criteria for intubation</title><p id="Par20">Clinical variables, respiratory variables and blood gas samples were collected at two time points. First, at randomization in the original parent trial, during spontaneous breathing with a non-rebreathing mask, termed &#x0201c;baseline&#x0201d; in the present post hoc analysis. Second, 1&#x000a0;h after initiation of the allocated treatment by the randomization in the parent trial (standard oxygen, HFOT or NIV) [<xref ref-type="bibr" rid="CR1">1</xref>]. To assess the intensity of dyspnea, patients were asked to rate their breathing discomfort (in French &#x0201c;<italic>inconfort respiratoire</italic>&#x0201d;) by placing a cursor on a 100&#x000a0;mm visual analog scale (dyspnea-VAS) bounded on the left by &#x0201c;no respiratory discomfort&#x0201d; and on the right by &#x0201c;worst imaginable respiratory discomfort.&#x0201d; Of notice, this question did not target discomfort associated with the respiratory interface. Dyspnea-VAS was used to identify four groups of patients: no dyspnea (dyspnea-VAS&#x02009;&#x0003c;&#x02009;16&#x000a0;mm), mild dyspnea (dyspnea-VAS between 16 and 39&#x000a0;mm), moderate dyspnea (dyspnea-VAS between 40 and 64&#x000a0;mm), and severe dyspnea (dyspnea-VAS&#x02009;&#x02265;&#x02009;65&#x000a0;mm). The 40&#x000a0;mm cutoff was based on the 2024 <italic>European Respiratory Society/European Society of Intensive Care Medicine</italic> joint statement on dyspnea in critically ill patients [<xref ref-type="bibr" rid="CR11">11</xref>] and on the many similar features shared by dyspnea and pain (noxious sensations, common pathways, similar cortical areas involved and affective dimension) [<xref ref-type="bibr" rid="CR22">22</xref>]. The 16&#x000a0;mm and 65&#x000a0;mm cutoffs were based on the first and third quartile of dyspnea-VAS at baseline in our cohort.</p><p id="Par21">The need for invasive mechanical ventilation was defined in the original parent trial by the following prespecified criteria for endotracheal intubation: (1) signs of persisting or worsening respiratory failure, including at least two of the following criteria: respiratory rate above 40&#x000a0;breaths/min, lack of improvement of signs of high respiratory muscle workload, development of copious tracheal secretions, pH below 7.35, or SpO<sub>2</sub> below 90% for more than 5&#x000a0;min; (2) hemodynamic instability; or (3) deterioration of neurologic status [<xref ref-type="bibr" rid="CR1">1</xref>]. Of note, dyspnea was not among these criteria. Intensive care unit mortality and 90-day mortality were recorded.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par22">Quantitative variables were described as median (interquartile range). Qualitative variables were described as frequency (percentages). Five outcomes were analyzed: two qualitative outcomes, dyspnea at baseline and dyspnea 1&#x000a0;h after randomization, one quantitative outcome, the difference between dyspnea intensity at baseline and dyspnea 1&#x000a0;h after randomization and two censored outcomes, time from enrollment to intubation (with discharge from ICU as a competitive event) and 90-day mortality, defined as the time from enrollment to death. Patients alive at 90&#x000a0;days were censored at 90&#x000a0;days, and patients lost to follow-up were censored to their last known contact.</p><p id="Par23">Factors associated with moderate-to-severe dyspnea at baseline and after the first hour were studied by multivariate logistic regression analysis. The multivariate model was built with the following variables that were considered to be clinically relevant: age, smoker, immunosuppression status, McCabe score, heart rate, systolic arterial pressure, respiratory rate, bilateral pulmonary infiltrates, PaO<sub>2</sub>/FiO<sub>2</sub> and randomization arm in the parent trial (oxygenation strategy). Adjusted odds ratios (OR) were presented with their 95% confidence intervals (CI). Factors associated with the change in dyspnea intensity between baseline and the first hour were studied using a multivariable linear regression model, taking into account the same variables as well as dyspnea intensity at baseline.</p><p id="Par24">Factors associated with time to intubation were studied using the Fine and Gray model with ICU discharge as a competing event [<xref ref-type="bibr" rid="CR23">23</xref>]. Cumulative incidence of intubation was estimated with the Kalbfleisch and Prentice method, considering ICU discharge as a competing event [<xref ref-type="bibr" rid="CR24">24</xref>]. These factors were compared using Gray&#x02019;s test [<xref ref-type="bibr" rid="CR25">25</xref>]. A first multivariate model was built with the following baseline variables that were considered to be clinically relevant: SAPS 2, randomization arm, bilateral pulmonary infiltrates, heart rate, systolic arterial pressure, respiratory rate, dyspnea and PaO<sub>2</sub>/FiO<sub>2</sub> at baseline. A second multivariate model was built with the following variables that were considered to be clinically relevant 1&#x000a0;h after treatment initiation: heart rate, arterial pressure, respiratory rate, dyspnea and PaO<sub>2</sub>/FiO<sub>2</sub> and change in dyspnea between baseline and 1&#x000a0;h after treatment initiation. Adjusted subdistribution hazard ratios (sHR) were presented with their 95% CI.</p><p id="Par25">Finally, the association between dyspnea and 90-day mortality was evaluated with a Cox proportional hazard model. Cumulative incidence curves for mortality were estimated using the Kaplan&#x02013;Meier estimator and compared using a log rank test. The multivariate model was built with the following variables that were considered to be clinically relevant: age, preexisting cardiac failure, immunosuppression, McCabe score, SAPS 2 on admission, SOFA score on inclusion, randomization arm, bilateral pulmonary infiltrates and dyspnea at baseline. Adjusted hazard ratios (HR) were presented with their 95% CI.</p><p id="Par26">For each model, validity assumptions were checked (log-linearity and proportional hazards assumptions) and multivariate models were built using a backward selection based on AIC (Akaike information criterion) criteria.</p><p id="Par27">Analyses were conducted at the two-sided &#x003b1; risk of 5%. No multiplicity test correction was made. All statistical analyses were performed with R statistical software, version 3.2.0 (available online at <ext-link ext-link-type="uri" xlink:href="http://www.r-project.org/">http://www.r-project.org/</ext-link> and package survival, cmprsk).</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Study population and prevalence of dyspnea</title><p id="Par28">Among the 313 patients included in the parent trial, three patients withdrew consent and quantification of dyspnea was missing in 51 patients at baseline and in 57 patients 1&#x000a0;h after treatment initiation (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>&#x000a0;Figure E1). Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> indicates the patient characteristics at baseline.
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Univariate analysis: factors associated with moderate-to-severe dyspnea at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" rowspan="2">All patients (<italic>n</italic>&#x02009;=&#x02009;259)</th><th align="left">No dyspnea (<italic>n</italic>&#x02009;=&#x02009;70)</th><th align="left">Mild dyspnea (<italic>n</italic>&#x02009;=&#x02009;43)</th><th align="left">Moderate dyspnea (<italic>n</italic>&#x02009;=&#x02009;84)</th><th align="left">Severe dyspnea (<italic>n</italic>&#x02009;=&#x02009;62)</th><th align="left" rowspan="2"><italic>p</italic> value</th></tr><tr><th align="left">Dyspnea-VAS&#x02009;&#x0003c;&#x02009;16&#x000a0;mm</th><th align="left">Dyspnea-VAS 16&#x02013;39&#x000a0;mm</th><th align="left">Dyspnea-VAS 40&#x02013;64&#x000a0;mm</th><th align="left">Dyspnea-VAS&#x02009;&#x02265;&#x02009;65&#x000a0;mm</th></tr></thead><tbody><tr><td align="left" colspan="7">Patient characteristics</td></tr><tr><td align="left">&#x000a0;Age, years, median (IQR)</td><td align="left">62 (48&#x02013;74)</td><td align="left">61 (46&#x02013;71)</td><td align="left">57 (45&#x02013;69)</td><td align="left">64 (48&#x02013;77)</td><td align="left">66 (53&#x02013;75)</td><td char="." align="char">0.128</td></tr><tr><td align="left">&#x000a0;Male gender<italic>, n</italic> (%)</td><td align="left">183 (71)</td><td align="left">49 (70)</td><td align="left">35 (81)</td><td align="left">54 (64)</td><td align="left">45 (73)</td><td char="." align="char">0.245</td></tr><tr><td align="left">&#x000a0;BMI, kg&#x000a0;m<sup>&#x02212;2</sup>, median (IQR)</td><td align="left">25 (22&#x02013;29)</td><td align="left">25 (22&#x02013;31)</td><td align="left">25 (21&#x02013;29)</td><td align="left">26 (23&#x02013;28)</td><td align="left">25 (22&#x02013;27)</td><td char="." align="char">0.407</td></tr><tr><td align="left">&#x000a0;Current or past smoking,<italic> n</italic> (%)</td><td align="left">94 (36)</td><td align="left">31 (44)</td><td align="left">19 (44)</td><td align="left">22 (26)</td><td align="left">22 (35)</td><td char="." align="char">0.078</td></tr><tr><td align="left">&#x000a0;Preexisting cardiac failure, <italic>n</italic> (%)</td><td align="left">16 (6)</td><td align="left">6 (9)</td><td align="left">0 (0)</td><td align="left">6 (7)</td><td align="left">4 (6)</td><td char="." align="char">0.250</td></tr><tr><td align="left">&#x000a0;Immunosuppression, <italic>n</italic> (%)</td><td align="left">70 (27)</td><td align="left">24 (34)</td><td align="left">19 (44)</td><td align="left">19 (23)</td><td align="left">8 (13)</td><td char="." align="char">0.002</td></tr><tr><td align="left" colspan="6">&#x000a0;McCabe</td><td char="." align="char">&#x0003c;&#x02009;0.003</td></tr><tr><td align="left">&#x000a0;&#x000a0;1, <italic>n</italic> (%)</td><td align="left">203 (78)</td><td align="left">49 (70)</td><td align="left">27 (63)</td><td align="left">70 (83)</td><td align="left">57 (92)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x000a0;2, <italic>n</italic> (%)</td><td align="left">48 (18)</td><td align="left">17 (24)</td><td align="left">14 (33)</td><td align="left">12 (14)</td><td align="left">5 (8)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x000a0;3, <italic>n</italic> (%)</td><td align="left">8 (3)</td><td align="left">4 (6)</td><td align="left">2 (5)</td><td align="left">2 (2)</td><td align="left">0 (0)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;SAPSII at inclusion, median (IQR)</td><td align="left">24 (19&#x02013;31)</td><td align="left">24 (20&#x02013;32)</td><td align="left">23 (18&#x02013;33)</td><td align="left">24 (19&#x02013;30)</td><td align="left">24 (18&#x02013;30)</td><td char="." align="char">0.948</td></tr><tr><td align="left">&#x000a0;SOFA at inclusion, median (IQR)</td><td align="left">3 (2&#x02013;5)</td><td align="left">3 (2&#x02013;4)</td><td align="left">3 (2&#x02013;5)</td><td align="left">3 (2&#x02013;5)</td><td align="left">3 (2&#x02013;5)</td><td char="." align="char">0.269</td></tr><tr><td align="left" colspan="7">Cause of ARF</td></tr><tr><td align="left">&#x000a0;Community-acquired pneumonia, <italic>n</italic> (%)</td><td align="left">167 (64)</td><td align="left">43 (61)</td><td align="left">24 (56)</td><td align="left">59 (70)</td><td align="left">41 (66)</td><td char="." align="char">0.394</td></tr><tr><td align="left">&#x000a0;Hospital-acquired pneumonia, <italic>n</italic> (%)</td><td align="left">34 (13)</td><td align="left">6 (9)</td><td align="left">11 (26)</td><td align="left">11 (13)</td><td align="left">6 (10)</td><td char="." align="char">0.051</td></tr><tr><td align="left">&#x000a0;Other, <italic>n</italic> (%)</td><td align="left">69 (27)</td><td align="left">24 (34)</td><td align="left">9 (21)</td><td align="left">17 (20)</td><td align="left">19 (31)</td><td char="." align="char">0.166</td></tr><tr><td align="left" colspan="7">At baseline, at randomization</td></tr><tr><td align="left">&#x000a0;Respiratory rate, min<sup>&#x02212;1</sup>, median (IQR)</td><td align="left">31 (27&#x02013;36)</td><td align="left">30 (27&#x02013;35)</td><td align="left">30 (27&#x02013;37)</td><td align="left">32 (28&#x02013;36)</td><td align="left">33 (28&#x02013;39)</td><td char="." align="char">0.408</td></tr><tr><td align="left">&#x000a0;Dyspnea-VAS, median (IQR)</td><td align="left">46 (13&#x02013;65)</td><td align="left">4 (0&#x02013;10)</td><td align="left">27 (21&#x02013;30)</td><td align="left">50 (48&#x02013;59)</td><td align="left">80 (74&#x02013;90)</td><td char="." align="char">0.001</td></tr><tr><td align="left">&#x000a0;Heart rate, min<sup>&#x02212;1</sup>, median (IQR)</td><td align="left">105 (93&#x02013;119)</td><td align="left">110 (92&#x02013;120)</td><td align="left">105 (92&#x02013;119)</td><td align="left">103 (92&#x02013;115)</td><td align="left">107 (96&#x02013;119)</td><td char="." align="char">0.509</td></tr><tr><td align="left">&#x000a0;Systolic arterial pressure, mmHg, median (IQR)</td><td align="left">121 (108&#x02013;140)</td><td align="left">120 (102&#x02013;134)</td><td align="left">120 (110&#x02013;141)</td><td align="left">121 (109&#x02013;141)</td><td align="left">122 (109&#x02013;139)</td><td char="." align="char">0.379</td></tr><tr><td align="left">&#x000a0;Bilateral pulmonary infiltrates, <italic>n</italic> (%)</td><td align="left">205 (79)</td><td align="left">52 (74)</td><td align="left">34 (79)</td><td align="left">65 (77)</td><td align="left">54 (87)</td><td char="." align="char">0.316</td></tr><tr><td align="left" colspan="7">&#x000a0;Blood gases</td></tr><tr><td align="left">&#x000a0;&#x000a0;PaO<sub>2</sub>/FiO<sub>2</sub>, mmHg, median (IQR)</td><td align="left">129 (98&#x02013;171)</td><td align="left">135 (103&#x02013;182)</td><td align="left">154 (92&#x02013;197)</td><td align="left">133 (105&#x02013;165)</td><td align="left">115 (96&#x02013;156)</td><td char="." align="char">0.231</td></tr><tr><td align="left">&#x000a0;&#x000a0;PaCO<sub>2</sub>, mmHg, median (IQR)</td><td align="left">36 (32&#x02013;39)</td><td align="left">35 (33&#x02013;39)</td><td align="left">36 (33&#x02013;39)</td><td align="left">35 (32&#x02013;38)</td><td align="left">36 (32&#x02013;39)</td><td char="." align="char">0.829</td></tr><tr><td align="left">&#x000a0;&#x000a0;pH, mmHg, median (IQR)</td><td align="left">7.44 (7.41&#x02013;7.47)</td><td align="left">7.43 (7.40&#x02013;7.47)</td><td align="left">7.44 (7.41&#x02013;7.46)</td><td align="left">7.44 (7.42&#x02013;7.47)</td><td align="left">7.44 (7.40&#x02013;7.46)</td><td char="." align="char">0.672</td></tr></tbody></table><table-wrap-foot><p><italic>VAS</italic> visual analog scale, <italic>IQR</italic> interquartile range, <italic>BMI</italic> body mass index, <italic>SAPS 2</italic> simplified acute physiology score, <italic>SOFA</italic> sequential organ failure assessment score, <italic>PaO</italic><sub><italic>2</italic></sub><italic>/FiO</italic><sub><italic>2</italic></sub> ratio of arterial oxygen tension to inspired oxygen fraction</p></table-wrap-foot></table-wrap></p><p id="Par29">At baseline, the intensity of dyspnea was 46 (16&#x02013;65) mm on the dyspnea-VAS (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) and dyspnea was mild (dyspnea-VAS between 16 and 39&#x000a0;mm) in 17% of patients, moderate (dyspnea-VAS between 40 and 64&#x000a0;mm) in 32% and severe (dyspnea-VAS&#x02009;&#x02265;&#x02009;65&#x000a0;mm) in 24%. After 1&#x000a0;h of treatment, the intensity of dyspnea score decreased to 35 (10&#x02013;56) mm (<italic>p</italic>&#x02009;=&#x02009;0.0004) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) and was mild in 22% of patients, moderate in 30% and severe in 17%. The median absolute variation of dyspnea was 10 (0&#x02013;20)&#x000a0;mm and decreased by 10&#x000a0;mm or more in 219 (51%) patients.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Box plots showing dyspnea-visual analog scale from zero (no respiratory discomfort) to 100&#x000a0;mm (worst imaginable respiratory discomfort) at baseline and 1&#x000a0;h after treatment initiation. The black center line denotes the median value (50th percentile), while the box contains the 25th to 75th percentiles of dataset. The blue line denotes the mean value. The black whiskers mark the maximal and minimal values</p></caption><graphic xlink:href="13054_2024_4903_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec8"><title>Factors associated with moderate-to-severe dyspnea at baseline and after 1&#x000a0;h of treatment</title><p id="Par30">Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> displays the factors associated with mild, moderate and severe dyspnea at baseline. On multivariate logistic regression analysis, three factors were independently associated with reduced risk of moderate-to-severe dyspnea (dyspnea-VAS&#x02009;&#x02265;&#x02009;40&#x000a0;mm) at baseline: smoking (OR 0.39, 95% CI 0.22&#x02013;0.69), immunosuppression (OR 0.48, 95% CI 0.25&#x02013;0.92) and McCabe 2 or 3 (OR 0.32, 95% CI 0.16&#x02013;0.65).</p><p id="Par31">Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> shows the factors associated with mild, moderate and severe dyspnea 1&#x000a0;h after treatment initiation. On multivariate logistic regression analysis, six of these factors were independently associated with moderate-to-severe dyspnea (dyspnea-VAS&#x02009;&#x02265;&#x02009;40&#x000a0;mm) 1&#x000a0;h after treatment initiation. Four factors were associated with increased risk of moderate-to-severe dyspnea: age&#x02009;&#x0003e;&#x02009;60&#x000a0;years (OR 2.17, 95% CI 1.20&#x02013;3.90), systolic arterial pressure 1&#x000a0;h after treatment initiation (OR per 10 points increased 1.13 95% CI 0.98&#x02013;1.30), respiratory rate 1&#x000a0;h after treatment initiation (OR per 10 points increased 1.43 95% CI 0.96&#x02013;2.13) and bilateral pulmonary infiltrates (OR 3.08, 95% CI 1.42&#x02013;6.65). Two factors were associated with reduced risk of moderate-to-severe dyspnea: immunodeficiency (OR 0.49, 95% CI 0.25&#x02013;0.97) and HFOT (OR 0.57, 95% CI 0.34&#x02013;0.95).
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Univariate analysis: factors associated with moderate-to-severe dyspnea 1&#x000a0;h after treatment initiation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" rowspan="2">All patients (<italic>n</italic>&#x02009;=&#x02009;253)</th><th align="left">No dyspnea (<italic>n</italic>&#x02009;=&#x02009;80)</th><th align="left">Mild dyspnea (<italic>n</italic>&#x02009;=&#x02009;55)</th><th align="left">Moderate dyspnea (<italic>n</italic>&#x02009;=&#x02009;75)</th><th align="left">Severe dyspnea (<italic>n</italic>&#x02009;=&#x02009;43)</th><th align="left" rowspan="2"><italic>p</italic> value</th></tr><tr><th align="left">Dyspnea-VAS&#x02009;&#x0003c;&#x02009;16&#x000a0;mm</th><th align="left">Dyspnea-VAS 16&#x02013;39&#x000a0;mm</th><th align="left">Dyspnea-VAS 40&#x02013;64&#x000a0;mm</th><th align="left">Dyspnea-VAS&#x02009;&#x02265;&#x02009;65&#x000a0;mm</th></tr></thead><tbody><tr><td align="left" colspan="7">Patient characteristics</td></tr><tr><td align="left">&#x000a0;Age, years, median (IQR)</td><td align="left">60 (48&#x02013;72)</td><td align="left">56 (45&#x02013;70)</td><td align="left">59 (52&#x02013;71)</td><td align="left">62 (49&#x02013;72)</td><td align="left">69 (56&#x02013;80)</td><td char="." align="char">0.032</td></tr><tr><td align="left">&#x000a0;Male gender, <italic>n</italic> (%)</td><td align="left">178 (70)</td><td align="left">54 (68)</td><td align="left">42 (76)</td><td align="left">51 (68)</td><td align="left">31 (72)</td><td char="." align="char">0.676</td></tr><tr><td align="left">&#x000a0;BMI, kg&#x000a0;m<sup>&#x02212;2</sup>, median (IQR)</td><td align="left">25 (22&#x02013;29)</td><td align="left">25 (22&#x02013;31)</td><td align="left">25 (22&#x02013;28)</td><td align="left">24 (22&#x02013;28)</td><td align="left">26 (23&#x02013;27)</td><td char="." align="char">0.627</td></tr><tr><td align="left">&#x000a0;Current or past smoking, <italic>n</italic> (%)</td><td align="left">94 (37)</td><td align="left">32 (40)</td><td align="left">19 (35)</td><td align="left">28 (37)</td><td align="left">15 (35)</td><td char="." align="char">0.911</td></tr><tr><td align="left">&#x000a0;Preexisting cardiac failure, <italic>n</italic> (%)</td><td align="left">15 (6)</td><td align="left">5 (6)</td><td align="left">1 (2)</td><td align="left">5 (7)</td><td align="left">4 (9)</td><td char="." align="char">0.444</td></tr><tr><td align="left">&#x000a0;Immunosuppression, <italic>n</italic> (%)</td><td align="left">68 (27)</td><td align="left">29 (36)</td><td align="left">16 (29)</td><td align="left">17 (23)</td><td align="left">6 (14)</td><td char="." align="char">0.045</td></tr><tr><td align="left" colspan="6">&#x000a0;McCabe</td><td char="." align="char">0.017</td></tr><tr><td align="left">&#x000a0;&#x000a0;1, <italic>n</italic> (%)</td><td align="left">199 (79)</td><td align="left">54 (68)</td><td align="left">47 (85)</td><td align="left">62 (83)</td><td align="left">36 (84)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x000a0;2, <italic>n</italic> (%)</td><td align="left">48 (19)</td><td align="left">23 (29)</td><td align="left">5 (9)</td><td align="left">13 (17)</td><td align="left">7 (16)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x000a0;3, <italic>n</italic> (%)</td><td align="left">6 (2)</td><td align="left">3 (4)</td><td align="left">3 (5)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;SAPSII at inclusion, median (IQR)</td><td align="left">24 (18&#x02013;30)</td><td align="left">25 (20&#x02013;31)</td><td align="left">23 (19&#x02013;29)</td><td align="left">23 (18&#x02013;30)</td><td align="left">27 (19&#x02013;32)</td><td char="." align="char">0.391</td></tr><tr><td align="left">&#x000a0;SOFA at inclusion, median (IQR)</td><td align="left">3 (2&#x02013;4)</td><td align="left">3 (2&#x02013;5)</td><td align="left">3 (2&#x02013;4)</td><td align="left">3 (2&#x02013;5)</td><td align="left">3 (2&#x02013;4)</td><td char="." align="char">0.716</td></tr><tr><td align="left" colspan="7">Cause of ARF</td></tr><tr><td align="left">&#x000a0;Community-acquired pneumonia, <italic>n</italic> (%)</td><td align="left">168 (66)</td><td align="left">45 (56)</td><td align="left">42 (76)</td><td align="left">51 (68)</td><td align="left">30 (70)</td><td char="." align="char">0.092</td></tr><tr><td align="left">&#x000a0;Hospital-acquired pneumonia, <italic>n</italic> (%)</td><td align="left">33 (13)</td><td align="left">9 (11)</td><td align="left">8 (15)</td><td align="left">11 (15)</td><td align="left">5 (12)</td><td char="." align="char">0.900</td></tr><tr><td align="left">&#x000a0;Other, <italic>n</italic> (%)</td><td align="left">61 (24)</td><td align="left">28 (35)</td><td align="left">7 (13)</td><td align="left">16 (21)</td><td align="left">10 (23)</td><td char="." align="char">0.024</td></tr><tr><td align="left" colspan="6">Oxygenation strategy</td><td char="." align="char">0.091</td></tr><tr><td align="left">&#x000a0;Standard oxygen, <italic>n</italic> (%)</td><td align="left">77 (30)</td><td align="left">22 (28)</td><td align="left">17 (31)</td><td align="left">24 (32)</td><td align="left">14 (33)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;High flow oxygen therapy, <italic>n</italic> (%)</td><td align="left">87 (34)</td><td align="left">36 (45)</td><td align="left">22 (40)</td><td align="left">19 (25)</td><td align="left">10 (23)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Noninvasive ventilation, <italic>n</italic> (%)</td><td align="left">89 (35)</td><td align="left">22 (28)</td><td align="left">16 (29)</td><td align="left">32 (43)</td><td align="left">19 (44)</td><td char="." align="char"/></tr><tr><td align="left" colspan="7">One hour after treatment initiation</td></tr><tr><td align="left">&#x000a0;Respiratory rate, min<sup>&#x02212;1</sup>, median (IQR)</td><td align="left">29 (24&#x02013;35)</td><td align="left">29 (24&#x02013;35)</td><td align="left">27 (21&#x02013;33)</td><td align="left">30 (25&#x02013;35)</td><td align="left">31 (27&#x02013;37)</td><td char="." align="char">0.017</td></tr><tr><td align="left">&#x000a0;Dyspnea-VAS, median (IQR)</td><td align="left">35 (10&#x02013;56)</td><td align="left">4 (0&#x02013;9)</td><td align="left">28 (23&#x02013;31)</td><td align="left">50 (46&#x02013;57)</td><td align="left">80 (75&#x02013;90)</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x000a0;Heart rate, min<sup>&#x02212;1</sup>, median (IQR)</td><td align="left">101 (90&#x02013;115)</td><td align="left">103 (89&#x02013;117)</td><td align="left">100 (86&#x02013;109)</td><td align="left">104 (90&#x02013;116)</td><td align="left">100 (93&#x02013;118)</td><td char="." align="char">0.248</td></tr><tr><td align="left">&#x000a0;Systolic arterial pressure, mmHg, median (IQR)</td><td align="left">120 (108&#x02013;139)</td><td align="left">119 (103&#x02013;131)</td><td align="left">118 (106&#x02013;134)</td><td align="left">130(113&#x02013;145)</td><td align="left">120 (107&#x02013;141)</td><td char="." align="char">0.012</td></tr><tr><td align="left" colspan="7">&#x000a0;Blood gases</td></tr><tr><td align="left">&#x000a0;&#x000a0;PaO<sub>2</sub>/FiO<sub>2</sub>, mmHg, median (IQR)</td><td align="left">133 (103 &#x02013;173)</td><td align="left">145 (104&#x02013;187)</td><td align="left">147 (105&#x02013;179)</td><td align="left">131 (96&#x02013;165)</td><td align="left">118 (100&#x02013;157)</td><td char="." align="char">0.296</td></tr><tr><td align="left">&#x000a0;&#x000a0;PaCO<sub>2</sub>, mmHg, median (IQR)</td><td align="left">35 (31&#x02013;39)</td><td align="left">35 (30&#x02013;38)</td><td align="left">36 (31&#x02013;40)</td><td align="left">35 (31&#x02013;38)</td><td align="left">35 (30&#x02013;40)</td><td char="." align="char">0.874</td></tr><tr><td align="left">&#x000a0;&#x000a0;pH, mmHg, median (IQR)</td><td align="left">7.44 (7.41&#x02013;7.47)</td><td align="left">7.45 (7.41&#x02013;7.48)</td><td align="left">7.44 (7.4&#x02013;7.47)</td><td align="left">7.45 (7.43&#x02013;7.47)</td><td align="left">7.43 (7.41&#x02013;7.46)</td><td char="." align="char">0.259</td></tr></tbody></table><table-wrap-foot><p><italic>VAS</italic> visual analog scale, <italic>IQR</italic> interquartile range, <italic>BMI</italic> body mass index, <italic>SAPS 2</italic> simplified acute physiology score, <italic>SOFA</italic> sequential organ failure assessment score, <italic>PaO</italic><sub><italic>2</italic></sub><italic>/FiO</italic><sub><italic>2</italic></sub> ratio of arterial oxygen tension to inspired oxygen fraction</p></table-wrap-foot></table-wrap></p><p id="Par32">On multivariable linear regression model, two factors were associated with the change in dyspnea-VAS between baseline and 1&#x000a0;h after treatment initiation: dyspnea-VAS at baseline (&#x02212;&#x02009;0.38&#x02009;&#x000b1;&#x02009;0.05, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and noninvasive respiratory support (&#x02212;&#x02009;7.09&#x02009;&#x000b1;&#x02009;3.35 for HFOT and 2.56&#x02009;&#x000b1;&#x02009;3.36 for noninvasive ventilation as compared to standard oxygen, <italic>p</italic>&#x02009;=&#x02009;0.011) (Additional file <xref rid="MOESM1" ref-type="media">1</xref>, Table E1). There was no difference between treatment groups at baseline in terms of dyspnea intensity. However, 1&#x000a0;h after treatment initiation, dyspnea-VAS decreased in the HFOT group, while it did not change in the two other groups (Additional file <xref rid="MOESM1" ref-type="media">1</xref>, Table E2).</p></sec><sec id="Sec9"><title>Association between dyspnea and intubation</title><p id="Par33">This analysis excluded three do-not-intubate patients who died without being intubated. The intubation rate was 45% (<italic>n</italic>&#x02009;=&#x02009;115).</p><p id="Par34">Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> displays the baseline variables associated with intubation while accounting for ICU discharge as a time-dependent competing risk. On Fine and Gray&#x02019;s multivariate regression analysis, four variables were independently associated with intubation (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Three variables were associated with a higher risk of intubation: moderate (dyspnea-VAS 40&#x02013;64&#x000a0;mm) and severe (dyspnea-VAS&#x02009;&#x02265;&#x02009;65&#x000a0;mm) dyspnea at baseline (sHR 1.96, 95% CI 1.07&#x02013;3.57 and sHR 2.61, 95% CI 1.40&#x02013;4.87), baseline systolic arterial pressure 120&#x02013;140&#x000a0;mmHg (sHR 2.56, 95% CI 1.58&#x02013;4.17) and heart rate&#x02009;&#x0003e;&#x02009;100 beat/min at baseline (sHR 1.94, 95% CI 1.29&#x02013;2.92). One variable, baseline PaO<sub>2</sub>/FiO<sub>2</sub>&#x02009;&#x0003e;&#x02009;200&#x000a0;mmHg (sHR 0.34, 95% CI 0.15&#x02013;0.76), was associated with a lower risk of intubation. The cumulative incidence of intubation was higher in patients with moderate-to-severe dyspnea at baseline than in those with no or mild dyspnea (<italic>p</italic>&#x02009;=&#x02009;0.0004) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). There was no significant interaction between dyspnea and the randomization group (<italic>p</italic>&#x02009;=&#x02009;0.071).
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Univariate analysis: factors associated with intubation at baseline (n&#x02009;=&#x02009;256)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2">Univariate analysis</th><th align="left" colspan="2">Multivariate analysis</th></tr><tr><th align="left">Subdistribution hazard ratio (95% confidence interval)</th><th align="left"><italic>p</italic> value</th><th align="left">Subdistribution hazard ratio (95% confidence interval)</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="5">Patient characteristics</td></tr><tr><td align="left">&#x000a0;Age&#x02009;&#x0003e;&#x02009;60&#x000a0;years</td><td align="left">1.49 (1.04&#x02013;2.14)</td><td align="left">0.030</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Gender male</td><td align="left">1.22 (0.81&#x02013;1.82)</td><td align="left">0.345</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;BMI</td><td align="left"/><td align="left">0.672</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;25&#x02013;30&#x000a0;kg&#x000a0;m<sup>&#x02212;2</sup></td><td align="left">1.02 (0.67&#x02013;1.54)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x0003e;&#x02009;30&#x000a0;kg&#x000a0;m<sup>&#x02212;2</sup></td><td align="left">0.82 (0.51&#x02013;1.32)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Current or past smoking</td><td align="left">1.16 (0.81&#x02013;1.67)</td><td align="left">0.428</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Preexisting cardiac failure</td><td align="left">1.02 (0.52&#x02013;2.02)</td><td align="left">0.957</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Immunosuppression</td><td align="left">0.92 (0.64&#x02013;1.34)</td><td align="left">0.679</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;McCabe 2 or 3</td><td align="left">0.79 (0.52&#x02013;1.21)</td><td align="left">0.284</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;SAPS II&#x02009;&#x0003e;&#x02009;25</td><td align="left">1.46 (1.02&#x02013;2.10)</td><td align="left">0.038</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;SOFA at inclusion, per 10 points</td><td align="left">1.02 (0.93&#x02013;1.13)</td><td align="left">0.621</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Bilateral pulmonary infiltrates</td><td align="left">1.73 (1.05&#x02013;2.85)</td><td align="left">0.032</td><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="5">Cause of ARF</td></tr><tr><td align="left">&#x000a0;Community-acquired pneumonia</td><td align="left">0.82 (0.57&#x02013;1.17)</td><td align="left">0.268</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Hospital-acquired pneumonia</td><td align="left">1.27 (0.76&#x02013;2.13)</td><td align="left">0.365</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Other</td><td align="left">1.17 (0.81&#x02013;1.71)</td><td align="left">0.402</td><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="5">At baseline, at randomization</td></tr><tr><td align="left">&#x000a0;Respiratory rate&#x02009;&#x02265;&#x02009;30&#x000a0;min<sup>&#x02212;1</sup></td><td align="left">1.49 (1.03&#x02013;2.17)</td><td align="left">0.035</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Dyspnea-VAS</td><td align="left"/><td align="left">&#x0003c;&#x02009;0.001</td><td align="left"/><td align="left">0.023</td></tr><tr><td align="left">&#x000a0;16&#x02013;39&#x000a0;mm</td><td align="left">1.81 (0.95&#x02013;3.45)</td><td align="left"/><td align="left">1.54 (0.76&#x02013;3.12)</td><td align="left"/></tr><tr><td align="left">&#x000a0;40&#x02013;64&#x000a0;mm</td><td align="left">2.04 (1.19&#x02013;3.48)</td><td align="left"/><td align="left">1.96 (1.07&#x02013;3.57)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02265;&#x02009;65&#x000a0;mm</td><td align="left">3.31 (1.92&#x02013;5.68)</td><td align="left"/><td align="left">2.61 (1.40&#x02013;4.87)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Heart rate&#x02009;&#x02265;&#x02009;100 beat min<sup>&#x02212;1</sup></td><td align="left">1.72 (1.16&#x02013;2.55)</td><td align="left">0.007</td><td align="left">1.94 (1.29&#x02013;2.92)</td><td align="left">0.002</td></tr><tr><td align="left">&#x000a0;Systolic arterial pressure</td><td align="left"/><td align="left">&#x0003c;&#x02009;0.001</td><td align="left"/><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x000a0;120&#x02013;140&#x000a0;mmHg</td><td align="left">2.21 (1.47&#x02013;3.33)</td><td align="left"/><td align="left">2.56 (1.58&#x02013;4.17)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x0003e;&#x02009;140&#x000a0;mmHg</td><td align="left">1.55 (0.96&#x02013;2.51)</td><td align="left"/><td align="left">1.59 (0.94&#x02013;2.71)</td><td align="left"/></tr><tr><td align="left" colspan="5">&#x000a0;Blood gases</td></tr><tr><td align="left">&#x000a0;&#x000a0;PaO<sub>2</sub>/FiO<sub>2</sub></td><td align="left"/><td align="left">0.043</td><td align="left"/><td align="left">0.031</td></tr><tr><td align="left">&#x000a0;&#x000a0;100&#x02013;200&#x000a0;mmHg</td><td align="left">0.90 (0.58&#x02013;1.40)</td><td align="left"/><td align="left">0.77 (0.47&#x02013;1.24)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x0003e;&#x02009;200&#x000a0;mmHg</td><td align="left">0.43 (0.22&#x02013;0.86)</td><td align="left"/><td align="left">0.34 (0.15&#x02013;0.76)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;PaCO<sub>2</sub>&#x02009;&#x0003e;&#x02009;35&#x000a0;mmHg</td><td align="left">0.99 (0.69&#x02013;1.41)</td><td align="left">0.942</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;pH&#x02009;&#x02265;&#x02009;7.40</td><td align="left">1.07 (0.65&#x02013;1.77)</td><td align="left">0.787</td><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="2">Noninvasive respiratory support (randomization arm)</td><td align="left">0.067</td><td align="left"/><td align="left">0.132</td></tr><tr><td align="left">&#x000a0;Standard oxygen therapy</td><td align="left">1</td><td align="left"/><td align="left">1</td><td align="left"/></tr><tr><td align="left">&#x000a0;High flow oxygen therapy</td><td align="left">0.60 (0.38&#x02013;0.95)</td><td align="left"/><td align="left">0.61 (0.36&#x02013;1.04)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Noninvasive ventilation</td><td align="left">0.92 (0.60&#x02013;1.40)</td><td align="left"/><td align="left">0.95 (0.58&#x02013;1.56)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>The following variables were included in the initial complete model: SAPS 2, randomization arm, bilateral pulmonary infiltrates and heart rate, systolic arterial pressure, respiratory rate, dyspnea and PaO<sub>2</sub>/FiO<sub>2</sub> at baseline</p><p>The Area Under the Curve (AUC, 95% confidence interval) of the Fine and Gray model was 76 (70&#x02013;82)</p><p><italic>BMI</italic> body mass index, <italic>SAPS 2</italic> simplified acute physiology score, <italic>SOFA</italic> sequential organ failure assessment score, <italic>VAS</italic> visual analog scale, <italic>PaO</italic><sub><italic>2</italic></sub><italic>/FiO</italic><sub><italic>2</italic></sub> ratio of arterial oxygen tension to inspired oxygen fraction</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Cumulative incidence of intubation (solid line) while accounting for intensive care unit discharge (dashed line) among patients with no dyspnea at baseline (blue line), mild dyspnea (red line), moderate dyspnea (black line) and severe dyspnea (green line)</p></caption><graphic xlink:href="13054_2024_4903_Fig2_HTML" id="MO2"/></fig></p><p id="Par35">The variables measured 1&#x000a0;h after treatment initiation that were associated with a higher risk of intubation on Fine and Gray&#x02019;s multivariate regression analysis were severe dyspnea (dyspnea-VAS&#x02009;&#x02265;&#x02009;65&#x000a0;mm), high respiratory rate, high arterial blood pressure, high heart rate. A high PaO<sub>2</sub>/FiO<sub>2</sub> 1&#x000a0;h after treatment initiation was associated with a lower risk of intubation (Additional file <xref rid="MOESM1" ref-type="media">1</xref>, Table E3).</p></sec><sec id="Sec10"><title>Associations between dyspnea at baseline and mortality</title><p id="Par36">Intensive care unit mortality was 18% (<italic>n</italic>&#x02009;=&#x02009;46), and 90-day mortality was 20% (<italic>n</italic>&#x02009;=&#x02009;53). Ninety-day mortality was 16% (<italic>n</italic>&#x02009;=&#x02009;11) in patients with no dyspnea, 16% (<italic>n</italic>&#x02009;=&#x02009;6) in patients with mild dyspnea, 20% (<italic>n</italic>&#x02009;=&#x02009;17) in patients with moderate dyspnea and 31% (<italic>n</italic>&#x02009;=&#x02009;19) in patients with severe dyspnea (<italic>p</italic>&#x02009;=&#x02009;0.110). Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> shows the cumulative probability of survival up to 90&#x000a0;days in patients with no, mild, moderate and severe dyspnea (logrank test, <italic>p</italic>&#x02009;=&#x02009;0.086). The cumulative probability of survival was lower in patients with baseline dyspnea-VAS&#x02009;&#x02265;&#x02009;40&#x000a0;mm (logrank test, <italic>p</italic>&#x02009;=&#x02009;0.049) (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>, Figure E2).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Cumulative survival up to 90&#x000a0;days in patients with no dyspnea at baseline (blue line), mild dyspnea (red line), moderate dyspnea (black line) and severe dyspnea (green line)</p></caption><graphic xlink:href="13054_2024_4903_Fig3_HTML" id="MO3"/></fig></p><p id="Par37">On the multivariate Cox proportional hazard model, three factors remained in the final model and were associated with an increased 90-day mortality: SAPS 2&#x02009;&#x02265;&#x02009;25, moderate-to-severe dyspnea at baseline, PaO<sub>2</sub>/FiO<sub>2</sub> and treatment arm (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).
<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Factors associated with 90-day mortality (n&#x02009;=&#x02009;259)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2">Univariate analysis</th><th align="left" colspan="2">Multivariate analysis</th></tr><tr><th align="left">Hazard ratio (95% confidence interval)</th><th align="left"><italic>p</italic> value</th><th align="left">Hazard ratio 95% (confidence interval)</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="5">Patient characteristics</td></tr><tr><td align="left">&#x000a0;Age&#x02009;&#x0003e;&#x02009;60&#x000a0;years</td><td align="left">2.45 (1.39&#x02013;4.32)</td><td char="." align="char">0.001</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Gender male</td><td align="left">0.99 (0.56&#x02013;1.75)</td><td char="." align="char">0.979</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" colspan="2">&#x000a0;BMI</td><td char="." align="char">0.945</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x000a0;25&#x02013;30&#x000a0;kg&#x000a0;m<sup>&#x02212;2</sup></td><td align="left">0.97 (0.53&#x02013;1.77)</td><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x0003e;&#x02009;30&#x000a0;kg&#x000a0;m<sup>&#x02212;2</sup></td><td align="left">1.09 (9.56&#x02013;2.13)</td><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Current or past smoking</td><td align="left">0.71 (0.40&#x02013;1.26)</td><td char="." align="char">0.240</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Preexisting cardiac failure</td><td align="left">2.03 (0.87&#x02013;4.72)</td><td char="." align="char">0.095</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Immunosuppression</td><td align="left">1.32 (0.76&#x02013;2.28)</td><td char="." align="char">0.327</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;McCabe 2 or 3</td><td align="left">1.59 (0.90&#x02013;2.80)</td><td char="." align="char">0.108</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;SAPS II&#x02009;&#x02265;&#x02009;25</td><td align="left">3.56 (1.95&#x02013;6.51)</td><td char="." align="char">&#x0003c;&#x02009;0.001</td><td align="left">3.27 (1.68&#x02013;6.35)</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x000a0;SOFA at inclusion, per point</td><td align="left">1.16 (1.03&#x02013;1.31)</td><td char="." align="char">0.016</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Bilateral pulmonary infiltrates</td><td align="left">2.03 (0.92&#x02013;4.49)</td><td char="." align="char">0.072</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">Cause of ARF</td></tr><tr><td align="left">&#x000a0;Community-acquired pneumonia</td><td align="left">0.67 (0.40&#x02013;1.14)</td><td char="." align="char">0.135</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Hospital-acquired pneumonia</td><td align="left">1.50 (0.76&#x02013;2.97)</td><td char="." align="char">0.242</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Other</td><td align="left">1.45 (0.84&#x02013;2.51)</td><td char="." align="char">0.184</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">At baseline, at randomization</td></tr><tr><td align="left">&#x000a0;Respiratory rate&#x02009;&#x0003e;&#x02009;30&#x000a0;min<sup>&#x02212;1</sup></td><td align="left">1.49 (0.84&#x02013;2.63)</td><td char="." align="char">0.165</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" colspan="2">Dyspnea-VAS</td><td char="." align="char">0.086</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x000a0;16&#x02013;39&#x000a0;mm</td><td align="left">0.89 (0.33&#x02013;2.41)</td><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x000a0;40&#x02013;64&#x000a0;mm</td><td align="left">1.35 (0.63&#x02013;2.89)</td><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x02265;&#x02009;65&#x000a0;mm</td><td align="left">2.20 (1.05&#x02013;4.62)</td><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Moderate-to-severe dyspnea<sup>a</sup></td><td align="left">1.77 (0.99&#x02013;3.15)</td><td char="." align="char">0.049</td><td align="left">1.73 (0.93&#x02013;3.19)</td><td char="." align="char">0.073</td></tr><tr><td align="left">&#x000a0;Heart rate&#x02009;&#x0003e;&#x02009;100 beat min<sup>&#x02212;1</sup></td><td align="left">1.29 (0.74&#x02013;2.25)</td><td char="." align="char">0.373</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" colspan="2">&#x000a0;Systolic arterial pressure</td><td char="." align="char">0.034</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x000a0;120&#x02013;140&#x000a0;mmHg</td><td align="left">2.24 (1.19&#x02013;4.20)</td><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x0003e;&#x02009;140&#x000a0;mmHg</td><td align="left">1.69 (0.86&#x02013;3.33)</td><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left" colspan="5">&#x000a0;Blood gases</td></tr><tr><td align="left">&#x000a0;&#x000a0;PaO<sub>2</sub>/FiO<sub>2</sub></td><td align="left"/><td char="." align="char">0.056</td><td align="left"/><td char="." align="char">0.118</td></tr><tr><td align="left">&#x000a0;&#x000a0;100&#x02013;199&#x000a0;mmHg</td><td align="left">1.32 (.069&#x02013;2.53)</td><td char="." align="char"/><td align="left">1.27 (0.65&#x02013;2.46)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x0003e;&#x02009;200&#x000a0;mmHg</td><td align="left">0.35 (1.10&#x02013;1.25)</td><td char="." align="char"/><td align="left">0.36 (0.08&#x02013;1.64)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;PaCO<sub>2</sub>&#x02009;&#x0003e;&#x02009;<italic>35&#x000a0;mmHg</italic></td><td align="left">0.93(0.55&#x02013;1.57)</td><td char="." align="char">0.787</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;pH&#x02009;&#x02265;&#x02009;7.40</td><td align="left">0.75 (0.40&#x02013;1.42)</td><td char="." align="char">0.379</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" colspan="2">Noninvasive respiratory support (randomization arm)</td><td char="." align="char">0.042</td><td align="left"/><td char="." align="char">0.046</td></tr><tr><td align="left">&#x000a0;Standard oxygen therapy</td><td align="left">1</td><td char="." align="char"/><td align="left">1</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;High flow oxygen therapy</td><td align="left">0.48 (0.23&#x02013;0.99)</td><td char="." align="char"/><td align="left">0.43 (0.19&#x02013;1.01)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Noninvasive ventilation</td><td align="left">1.13 (0.63&#x02013;2.02)</td><td char="." align="char"/><td align="left">1.08 (0.58&#x02013;2.04)</td><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p>The following variables were included in the initial complete model: age, preexisting cardiac failure, immunosuppression, McCabe score, SAPS 2 on admission, SOFA score on inclusion, randomization arm, bilateral pulmonary infiltrates and dyspnea at baseline</p><p><italic>BMI</italic> body mass index, <italic>SAPS 2</italic> simplified acute physiology score, <italic>SOFA</italic> sequential organ failure assessment score, <italic>VAS</italic> visual analog scale, <italic>PaO</italic><sub><italic>2</italic></sub><italic>/FiO</italic><sub><italic>2</italic></sub> ratio of arterial oxygen tension to inspired oxygen fraction</p><p><sup>a</sup>Moderate-to severe dyspnea is defined as a dyspnea intensity&#x02009;&#x02265;&#x02009;40&#x000a0;mm on a visual analog scale from 0 to 100&#x000a0;mm</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec11"><title>Discussion</title><p id="Par38">In this ancillary study of patients admitted to the ICU for acute de novo hypoxemic ARF and treated either by noninvasive respiratory support, (1) the intensity of dyspnea at baseline was high, (2) moderate and severe dyspnea at baseline were independently associated with the risk of intubation, (3) moderate-to-severe dyspnea at baseline was also associated with 90-day mortality.</p><p id="Par39">To the best of our knowledge, this is the largest study to investigate dyspnea in a population of non-intubated patients admitted for de novo hypoxemic ARF. Dyspnea has been measured as a secondary outcome in many trials [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>] and has also been measured in a large heterogeneous population of patients receiving NIV [<xref ref-type="bibr" rid="CR13">13</xref>]. However, the prevalence of dyspnea and its risk factors and prognostic impact have not been previously studied in a large and homogeneous population.</p><p id="Par40">A major finding of our study is that poor respiratory comfort was independently associated with intubation, which has been previously reported in patients receiving NIV for ARF, for COVID-19, and in those with chronic obstructive pulmonary disease exacerbation [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. This may be considered as an obvious finding, since the intensity of dyspnea is a marker of ARF severity and subsequently a symptom that physicians integrate into their intubation decision-making process. However, as opposed to signs of respiratory distress that are observed by the physician [<xref ref-type="bibr" rid="CR32">32</xref>], dyspnea is a symptom that can only be self-reported by the patient. No study has scientifically evaluated this hypothesis, and we are not aware of physicians clearly asking their patients whether they are dyspneic or not when intubation is considered. In addition, in our study, dyspnea per se was not one of the prespecified criteria of intubation in the parent trial [<xref ref-type="bibr" rid="CR1">1</xref>]. Subsequently, dyspnea was not supposed to be taken into account by the physician when she or he decided to intubate the patient. Dyspnea was also associated with higher mortality in our study, reinforcing the belief that dyspnea is a proxy for the severity of ARF [<xref ref-type="bibr" rid="CR33">33</xref>]. This is in line with previous studies showing an association between poor respiratory comfort and hospital mortality in patients with suspected acute myocardial infarction [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], in those admitted for acute COPD exacerbation [<xref ref-type="bibr" rid="CR36">36</xref>] and even in patients without previously diagnosed cardiopulmonary diseases [<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>]. Dyspnea is associated with a higher intubation rate in COVID-19 patients [<xref ref-type="bibr" rid="CR14">14</xref>], and dyspnea upon hospital discharge is also associated with higher risk of readmission or death [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par41">Our study highlighted the high intensity of dyspnea in patients managed for ARF in the ICU, with around half of patients reporting dyspnea of an intensity&#x02009;&#x02265;&#x02009;40&#x000a0;mm. Similar pain intensity corresponds to the three most painful procedures experienced by ICU patients [<xref ref-type="bibr" rid="CR42">42</xref>], and these patients should receive analgesia promptly [<xref ref-type="bibr" rid="CR22">22</xref>]. Dyspnea can be considered as a key feature of ARF, and therefore, it is not surprising to observe such a high level of dyspnea in these patients. However, it should deserve consideration and should be managed and be controlled rapidly, like pain, to mitigate the immediate suffering and anxiety that are strongly associated with dyspnea [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Indeed, dyspnea rated as&#x02009;&#x02265;&#x02009;30/100&#x000a0;mm is considered to be unacceptable by one third of patients [<xref ref-type="bibr" rid="CR44">44</xref>]. Moreover, dyspnea is involved in the dark recollections of patients following their ICU stay [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>] and contributes to the pathogenesis of post-traumatic stress disorders [<xref ref-type="bibr" rid="CR47">47</xref>]. Without doubt, the relief of dyspnea is currently considered by some authors to be a basic human right [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Educational actions are needed to ensure that identification and management of dyspnea are performed as routinely as for pain. A previous study has shown that detection of moderate-to-severe dyspnea by nurses was not followed by any therapeutic intervention, in contrast to the detection of pain, which was significantly associated with the administration of opioids [<xref ref-type="bibr" rid="CR50">50</xref>]. There is also an urgent need to develop and validate clinical approaches to relieve dyspnea independently from the correction of its cause, exactly as in the case of pain [<xref ref-type="bibr" rid="CR49">49</xref>].</p><p id="Par42">The major strengths of our study are the prospective collection of data, especially for dyspnea level, the prespecified intubation criteria that did not include dyspnea and the multicenter design. This study presents limitations that need to be acknowledged. First, we quantified respiratory comfort at only two time points, at baseline and after 1&#x000a0;h. A longitudinal analysis based on multiple repeated measurements could provide additional results [<xref ref-type="bibr" rid="CR31">31</xref>]. However, a substantial proportion of patients were intubated in the first hours of management, which causes a significant drop-off. Second, patients were not systematically assessed for delirium, which may affect the self-reporting of dyspnea. However, dyspnea was not collected in patients who were unable to provide clear and coherent answers. Third, patients were asked to quote their breathing discomfort, which is not exactly dyspnea. Although terms such as &#x0201c;feeling breathlessness,&#x0201d; &#x0201c;shortness of breath&#x0201d; or &#x0201c;troubles breathing,&#x0201d; and &#x0201c;getting enough air&#x0201d; could have been used, none of them reflects perfectly dyspnea and a recent statement recognizes &#x0201c;breathing discomfort&#x0201d; as a proxy for dyspnea [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par43"><italic>In conclusion</italic>, this study showed that dyspnea is frequent and of a high intensity in a large proportion of critically ill patients with de novo hypoxemic ARF. Moderate-to-severe dyspnea is associated with poor outcomes and seems to be a threatening signal in these patients. As this symptom is easy to identify at the bedside, dyspnea could become a variable that is measured on a regular basis, like respiratory rate and pain intensity. Future studies are needed to evaluate the benefit of this systematic measurement on patient management and post ICU burden. Future studies should also develop strategies to relieve dyspnea, exactly as in the case of pain.</p></sec><sec id="Sec12" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13054_2024_4903_MOESM1_ESM.pdf"><caption><p><bold>Additional file 1</bold>. Supplementary figures and tables.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ICU</term><def><p id="Par6">Intensive care unit</p></def></def-item><def-item><term>ARF</term><def><p id="Par7">Acute respiratory failure</p></def></def-item><def-item><term>NIV</term><def><p id="Par8">Noninvasive ventilation</p></def></def-item><def-item><term>HFOT</term><def><p id="Par9">High-flow oxygen therapy</p></def></def-item><def-item><term>PaO<sub>2</sub>/FiO<sub>2</sub></term><def><p id="Par10">Ratio of arterial oxygen partial pressure to fractional inspired oxygen</p></def></def-item><def-item><term>SpO<sub>2</sub></term><def><p id="Par11">Pulse oxygen saturation</p></def></def-item><def-item><term>VAS</term><def><p id="Par12">Visual analog scale</p></def></def-item><def-item><term>OR</term><def><p id="Par13">Odds ratios</p></def></def-item><def-item><term>CI</term><def><p id="Par14">95% Confidence intervals</p></def></def-item><def-item><term>SHR</term><def><p id="Par15">Subdistribution hazard ratios</p></def></def-item></def-list></glossary><fn-group><fn><p>The original online version of this article was revised: the authors identified errors in Tables 1-3. In addition to these errors, there are some values that were not rounded, with decimals lefts.
None of these errors changes the original message and accuracy of the analysis.</p></fn><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p><bold>Change history</bold></p><p>2/26/2025</p><p>A Correction to this paper has been published: 10.1186/s13054-025-05314-w</p></fn></fn-group><ack><title>Acknowledgements</title><p>Nick Walker has edited the manuscript for English.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>AD, AB, LB and JPF designed the study. AD coordinated the study. AD, GP, AM, CG, GC, TB, SP, AT, JPF and TS were responsible for patient screening, enrollment and follow-up. AD, AB, SR, LB and MD analyzed the data. AD, TS and JPF wrote the manuscript. All authors contributed to draft the manuscript or revised it critically for important intellectual content and approved the final version of the manuscript. AD, AB, LB and JPF had full access to all of the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis, including and especially any adverse effects.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by a grant from the French Ministry of Health.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par44">The original parent trial was approved by ethics committees at Centre Hospitalier Universitaire de Poitiers for French study sites (n. 10.11.28, 28 December 2010) and at Cliniques Universitaires Saint-Luc, Brussels for the site in Belgium (n. 10.07.12, 3 May 2011). Written informed consent was obtained from all the patients, their next of kin or another surrogate decision-maker as appropriate. According to French law, this post hoc analysis of the original study did not need additional ethics approval as no more data were collected for this analysis. Procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as most recently amended.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par45">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par46">A Demoule reports grants from French Ministry of Health, Assistance publique&#x02014;H&#x000f4;pitaux de Paris, Lungpacer, Respinor, consulting fees from Respinor, Lungpacer, Lowenstein, Tribunal administrative de Cergy, Liberate Medical, Payment or honoraria for lectures, presentations from Fisher &#x00026; Paykel, Baxter, Getinge, Astra, Agence Europ&#x000e9;enne Informatique, Mindray, support for attending meetings and/or travel from Lungpacer, outside the submitted work. A Baptiste has nothing to disclose. AW Thille reports payment or honoraria for lectures, presentations Fisher &#x00026; Paykel, GE Healthcare, Philips, support for attending meetings and/or travel Fisher &#x00026; Paykel, GE Healthcare, outside the submitted work. T Similowski reports grants from Lungpacer, consulting fees from ADEP Assistance, AstraZeneca France, Chiesi France, KPL consulting, Lungpacer Inc., Novartis France, TEVA France, Vitalaire, outside the submitted work. S Ragot has nothing to disclose G Prat has nothing to disclose A Mercat has nothing to disclose. C Girault reports payment or honoraria for lectures, presentations from Air Liquide Medical System, Medtronic, Dr&#x000e4;ger, support for attending meetings and/or travel from Fisher &#x00026; Paykel, GE healthcare, Air Liquide Medical System, outside the submitted work. G Carteau reports payment or honoraria for lectures, presentations Air Liquide Medical System Medtronic Dr&#x000e4;ger, support for attending meetings and/or travel from Air Liquide Medical System outside the submitted work. T Boulain has nothing to disclose. S Perbet has nothing to disclose. L Belin has nothing to disclose. JP Frat reports non-financial support from Fisher and Paykel Healthcare (the firm provided material and equipment to all the participating centers), grant from the French Ministry of Heath, AADAIRC, French society of intensive care for the parent study, grants from the French Ministry of Heath, Fisher and Paykel Healthcare, consulting fees from SOS Oxygene, payment or honoraria for lectures from Fisher and Paykel Healthcare, support for attending meetings and/or travel from Fisher and Paykel Healthcare and SOS Oxygene, outside the submitted work.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Frat</surname><given-names>J-P</given-names></name><name><surname>Thille</surname><given-names>AW</given-names></name><name><surname>Mercat</surname><given-names>A</given-names></name><name><surname>Girault</surname><given-names>C</given-names></name><name><surname>Ragot</surname><given-names>S</given-names></name><name><surname>Perbet</surname><given-names>S</given-names></name><etal/></person-group><article-title>High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><fpage>2185</fpage><lpage>2196</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1503326</pub-id><pub-id pub-id-type="pmid">25981908</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Frat J-P, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372:2185&#x02013;96.<pub-id pub-id-type="pmid">25981908</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x02019;Her</surname><given-names>E</given-names></name><name><surname>Deye</surname><given-names>N</given-names></name><name><surname>Lellouche</surname><given-names>F</given-names></name><name><surname>Taille</surname><given-names>S</given-names></name><name><surname>Demoule</surname><given-names>A</given-names></name><name><surname>Fraticelli</surname><given-names>A</given-names></name><etal/></person-group><article-title>Physiologic effects of noninvasive ventilation during acute lung injury</article-title><source>Am J Respir Crit Care Med</source><year>2005</year><volume>172</volume><fpage>1112</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.1164/rccm.200402-226OC</pub-id><pub-id pub-id-type="pmid">16081548</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">L&#x02019;Her E, Deye N, Lellouche F, Taille S, Demoule A, Fraticelli A, et al. Physiologic effects of noninvasive ventilation during acute lung injury. Am J Respir Crit Care Med. 2005;172:1112&#x02013;8.<pub-id pub-id-type="pmid">16081548</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Demoule</surname><given-names>A</given-names></name><name><surname>Chevret</surname><given-names>S</given-names></name><name><surname>Carlucci</surname><given-names>A</given-names></name><name><surname>Kouatchet</surname><given-names>A</given-names></name><name><surname>Jaber</surname><given-names>S</given-names></name><name><surname>Meziani</surname><given-names>F</given-names></name><etal/></person-group><article-title>Changing use of noninvasive ventilation in critically ill patients: trends over 15 years in francophone countries</article-title><source>Intensive Care Med</source><year>2016</year><volume>42</volume><fpage>82</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/s00134-015-4087-4</pub-id><pub-id pub-id-type="pmid">26464393</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Demoule A, Chevret S, Carlucci A, Kouatchet A, Jaber S, Meziani F, et al. Changing use of noninvasive ventilation in critically ill patients: trends over 15 years in francophone countries. Intensive Care Med. 2016;42:82&#x02013;92.<pub-id pub-id-type="pmid">26464393</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Carrillo</surname><given-names>A</given-names></name><name><surname>Gonzalez-Diaz</surname><given-names>G</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Martinez-Quintana</surname><given-names>ME</given-names></name><name><surname>Lopez-Martinez</surname><given-names>A</given-names></name><name><surname>Llamas</surname><given-names>N</given-names></name><etal/></person-group><article-title>Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure</article-title><source>Intensive Care Med</source><year>2012</year><volume>38</volume><fpage>458</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1007/s00134-012-2475-6</pub-id><pub-id pub-id-type="pmid">22318634</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Carrillo A, Gonzalez-Diaz G, Ferrer M, Martinez-Quintana ME, Lopez-Martinez A, Llamas N, et al. Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. Intensive Care Med. 2012;38:458&#x02013;66.<pub-id pub-id-type="pmid">22318634</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Thille</surname><given-names>AW</given-names></name><name><surname>Contou</surname><given-names>D</given-names></name><name><surname>Fragnoli</surname><given-names>C</given-names></name><name><surname>Cordoba-Izquierdo</surname><given-names>A</given-names></name><name><surname>Boissier</surname><given-names>F</given-names></name><name><surname>Brun-Buisson</surname><given-names>C</given-names></name></person-group><article-title>Non-invasive ventilation for acute hypoxemic respiratory failure: intubation rate and risk factors</article-title><source>Crit Care</source><year>2013</year><volume>17</volume><fpage>R269</fpage><pub-id pub-id-type="doi">10.1186/cc13103</pub-id><pub-id pub-id-type="pmid">24215648</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Thille AW, Contou D, Fragnoli C, Cordoba-Izquierdo A, Boissier F, Brun-Buisson C. Non-invasive ventilation for acute hypoxemic respiratory failure: intubation rate and risk factors. Crit Care. 2013;17:R269.<pub-id pub-id-type="pmid">24215648</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Bellani</surname><given-names>G</given-names></name><name><surname>Laffey</surname><given-names>JG</given-names></name><name><surname>Pham</surname><given-names>T</given-names></name><name><surname>Madotto</surname><given-names>F</given-names></name><name><surname>Fan</surname><given-names>E</given-names></name><name><surname>Brochard</surname><given-names>L</given-names></name><etal/></person-group><article-title>Noninvasive ventilation of patients with acute respiratory distress syndrome. Insights from the LUNG SAFE study</article-title><source>Am J Respir Crit Care Med</source><year>2017</year><volume>195</volume><fpage>67</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1164/rccm.201606-1306OC</pub-id><pub-id pub-id-type="pmid">27753501</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Bellani G, Laffey JG, Pham T, Madotto F, Fan E, Brochard L, et al. Noninvasive ventilation of patients with acute respiratory distress syndrome. Insights from the LUNG SAFE study. Am J Respir Crit Care Med. 2017;195:67&#x02013;77.<pub-id pub-id-type="pmid">27753501</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Antonelli</surname><given-names>M</given-names></name><name><surname>Conti</surname><given-names>G</given-names></name><name><surname>Moro</surname><given-names>ML</given-names></name><name><surname>Esquinas</surname><given-names>A</given-names></name><name><surname>Gonzalez-Diaz</surname><given-names>G</given-names></name><name><surname>Confalonieri</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predictors of failure of noninvasive positive pressure ventilation in patients with acute hypoxemic respiratory failure: a multi-center study</article-title><source>Intensive Care Med</source><year>2001</year><volume>27</volume><fpage>1718</fpage><lpage>1728</lpage><pub-id pub-id-type="doi">10.1007/s00134-001-1114-4</pub-id><pub-id pub-id-type="pmid">11810114</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Antonelli M, Conti G, Moro ML, Esquinas A, Gonzalez-Diaz G, Confalonieri M, et al. Predictors of failure of noninvasive positive pressure ventilation in patients with acute hypoxemic respiratory failure: a multi-center study. Intensive Care Med. 2001;27:1718&#x02013;28.<pub-id pub-id-type="pmid">11810114</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Roca</surname><given-names>O</given-names></name><name><surname>Caralt</surname><given-names>B</given-names></name><name><surname>Messika</surname><given-names>J</given-names></name><name><surname>Samper</surname><given-names>M</given-names></name><name><surname>Sztrymf</surname><given-names>B</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>G</given-names></name><etal/></person-group><article-title>An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy</article-title><source>Am J Respir Crit Care Med</source><year>2019</year><volume>199</volume><fpage>1368</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1164/rccm.201803-0589OC</pub-id><pub-id pub-id-type="pmid">30576221</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hern&#x000e1;ndez G, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med. 2019;199:1368&#x02013;76.<pub-id pub-id-type="pmid">30576221</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Frat</surname><given-names>J-P</given-names></name><name><surname>Ragot</surname><given-names>S</given-names></name><name><surname>Coudroy</surname><given-names>R</given-names></name><name><surname>Constantin</surname><given-names>J-M</given-names></name><name><surname>Girault</surname><given-names>C</given-names></name><name><surname>Prat</surname><given-names>G</given-names></name><etal/></person-group><article-title>Predictors of intubation in patients with acute hypoxemic respiratory failure treated with a noninvasive oxygenation strategy</article-title><source>Crit Care Med</source><year>2018</year><volume>46</volume><fpage>208</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000002818</pub-id><pub-id pub-id-type="pmid">29099420</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Frat J-P, Ragot S, Coudroy R, Constantin J-M, Girault C, Prat G, et al. Predictors of intubation in patients with acute hypoxemic respiratory failure treated with a noninvasive oxygenation strategy. Crit Care Med. 2018;46:208&#x02013;15.<pub-id pub-id-type="pmid">29099420</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Carteaux</surname><given-names>G</given-names></name><name><surname>Mill&#x000e1;n-Guilarte</surname><given-names>T</given-names></name><name><surname>De Prost</surname><given-names>N</given-names></name><name><surname>Razazi</surname><given-names>K</given-names></name><name><surname>Abid</surname><given-names>S</given-names></name><name><surname>Thille</surname><given-names>AW</given-names></name><etal/></person-group><article-title>Failure of noninvasive ventilation for de novo acute hypoxemic respiratory failure: role of tidal volume</article-title><source>Crit Care Med</source><year>2016</year><volume>44</volume><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000001379</pub-id><pub-id pub-id-type="pmid">26584191</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Carteaux G, Mill&#x000e1;n-Guilarte T, De Prost N, Razazi K, Abid S, Thille AW, et al. Failure of noninvasive ventilation for de novo acute hypoxemic respiratory failure: role of tidal volume. Crit Care Med. 2016;44:282&#x02013;90.<pub-id pub-id-type="pmid">26584191</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Demoule</surname><given-names>A</given-names></name><name><surname>Decavele</surname><given-names>M</given-names></name><name><surname>Antonelli</surname><given-names>M</given-names></name><name><surname>Camporota</surname><given-names>L</given-names></name><name><surname>Abroug</surname><given-names>F</given-names></name><name><surname>Adler</surname><given-names>D</given-names></name><etal/></person-group><article-title>Dyspnoea in acutely ill mechanically ventilated adult patients: an ERS/ESICM statement</article-title><source>Intensive Care Med</source><year>2024</year><volume>50</volume><fpage>159</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1007/s00134-023-07246-x</pub-id><pub-id pub-id-type="pmid">38388984</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Demoule A, Decavele M, Antonelli M, Camporota L, Abroug F, Adler D, et al. Dyspnoea in acutely ill mechanically ventilated adult patients: an ERS/ESICM statement. Intensive Care Med. 2024;50:159&#x02013;80.<pub-id pub-id-type="pmid">38388984</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Kindler</surname><given-names>F</given-names></name><name><surname>Gottfried</surname><given-names>SB</given-names></name><name><surname>Raux</surname><given-names>M</given-names></name><name><surname>Hug</surname><given-names>F</given-names></name><name><surname>Similowski</surname><given-names>T</given-names></name><etal/></person-group><article-title>Dyspnea and surface inspiratory electromyograms in mechanically ventilated patients</article-title><source>Intensive Care Med</source><year>2013</year><volume>39</volume><fpage>1368</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1007/s00134-013-2910-3</pub-id><pub-id pub-id-type="pmid">23575612</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Schmidt M, Kindler F, Gottfried SB, Raux M, Hug F, Similowski T, et al. Dyspnea and surface inspiratory electromyograms in mechanically ventilated patients. Intensive Care Med. 2013;39:1368&#x02013;76.<pub-id pub-id-type="pmid">23575612</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Dangers</surname><given-names>L</given-names></name><name><surname>Montlahuc</surname><given-names>C</given-names></name><name><surname>Kouatchet</surname><given-names>A</given-names></name><name><surname>Jaber</surname><given-names>S</given-names></name><name><surname>Meziani</surname><given-names>F</given-names></name><name><surname>Perbet</surname><given-names>S</given-names></name><etal/></person-group><article-title>Dyspnoea in patients receiving noninvasive ventilation for acute respiratory failure: prevalence, risk factors and prognostic impact: a prospective observational study</article-title><source>Eur Respir J</source><year>2018</year><volume>52</volume><fpage>1702637</fpage><pub-id pub-id-type="doi">10.1183/13993003.02637-2017</pub-id><pub-id pub-id-type="pmid">29976650</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Dangers L, Montlahuc C, Kouatchet A, Jaber S, Meziani F, Perbet S, et al. Dyspnoea in patients receiving noninvasive ventilation for acute respiratory failure: prevalence, risk factors and prognostic impact: a prospective observational study. Eur Respir J. 2018;52:1702637.<pub-id pub-id-type="pmid">29976650</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Menga</surname><given-names>LS</given-names></name><name><surname>Grieco</surname><given-names>DL</given-names></name><name><surname>Ros&#x000e0;</surname><given-names>T</given-names></name><name><surname>Cesarano</surname><given-names>M</given-names></name><name><surname>Delle Cese</surname><given-names>L</given-names></name><name><surname>Berardi</surname><given-names>C</given-names></name><etal/></person-group><article-title>Dyspnoea and clinical outcome in critically ill patients receiving noninvasive support for COVID-19 respiratory failure: post hoc analysis of a randomised clinical trial</article-title><source>ERJ Open Res</source><year>2021</year><volume>7</volume><fpage>00418</fpage><lpage>2021</lpage><pub-id pub-id-type="doi">10.1183/23120541.00418-2021</pub-id><pub-id pub-id-type="pmid">34611526</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Menga LS, Grieco DL, Ros&#x000e0; T, Cesarano M, Delle Cese L, Berardi C, et al. Dyspnoea and clinical outcome in critically ill patients receiving noninvasive support for COVID-19 respiratory failure: post hoc analysis of a randomised clinical trial. ERJ Open Res. 2021;7:00418&#x02013;2021.<pub-id pub-id-type="pmid">34611526</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Frat</surname><given-names>J-P</given-names></name><name><surname>Quenot</surname><given-names>J-P</given-names></name><name><surname>Badie</surname><given-names>J</given-names></name><name><surname>Coudroy</surname><given-names>R</given-names></name><name><surname>Guitton</surname><given-names>C</given-names></name><name><surname>Ehrmann</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of high-flow nasal cannula oxygen vs standard oxygen therapy on mortality in patients with respiratory failure due to COVID-19: the SOHO-COVID randomized clinical trial</article-title><source>JAMA</source><year>2022</year><volume>328</volume><fpage>1212</fpage><lpage>1222</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.15613</pub-id><pub-id pub-id-type="pmid">36166027</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Frat J-P, Quenot J-P, Badie J, Coudroy R, Guitton C, Ehrmann S, et al. Effect of high-flow nasal cannula oxygen vs standard oxygen therapy on mortality in patients with respiratory failure due to COVID-19: the SOHO-COVID randomized clinical trial. JAMA. 2022;328:1212&#x02013;22.<pub-id pub-id-type="pmid">36166027</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Azoulay</surname><given-names>E</given-names></name><name><surname>Lemiale</surname><given-names>V</given-names></name><name><surname>Mokart</surname><given-names>D</given-names></name><name><surname>Nseir</surname><given-names>S</given-names></name><name><surname>Argaud</surname><given-names>L</given-names></name><name><surname>P&#x000e8;ne</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effect of high-flow nasal oxygen vs standard oxygen on 28-day mortality in immunocompromised patients with acute respiratory failure: the HIGH randomized clinical trial</article-title><source>JAMA</source><year>2018</year><volume>320</volume><fpage>2099</fpage><lpage>2107</lpage><pub-id pub-id-type="doi">10.1001/jama.2018.14282</pub-id><pub-id pub-id-type="pmid">30357270</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Azoulay E, Lemiale V, Mokart D, Nseir S, Argaud L, P&#x000e8;ne F, et al. Effect of high-flow nasal oxygen vs standard oxygen on 28-day mortality in immunocompromised patients with acute respiratory failure: the HIGH randomized clinical trial. JAMA. 2018;320:2099&#x02013;107.<pub-id pub-id-type="pmid">30357270</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Lemiale</surname><given-names>V</given-names></name><name><surname>Mokart</surname><given-names>D</given-names></name><name><surname>Resche-Rigon</surname><given-names>M</given-names></name><name><surname>P&#x000e8;ne</surname><given-names>F</given-names></name><name><surname>Mayaux</surname><given-names>J</given-names></name><name><surname>Faucher</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial</article-title><source>JAMA</source><year>2015</year><volume>314</volume><fpage>1711</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.12402</pub-id><pub-id pub-id-type="pmid">26444879</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Lemiale V, Mokart D, Resche-Rigon M, P&#x000e8;ne F, Mayaux J, Faucher E, et al. Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA. 2015;314:1711&#x02013;9.<pub-id pub-id-type="pmid">26444879</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Ospina-Tasc&#x000f3;n</surname><given-names>GA</given-names></name><name><surname>Calder&#x000f3;n-Tapia</surname><given-names>LE</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>AF</given-names></name><name><surname>Zarama</surname><given-names>V</given-names></name><name><surname>G&#x000f3;mez-&#x000c1;lvarez</surname><given-names>F</given-names></name><name><surname>&#x000c1;lvarez-Saa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: a randomized clinical trial</article-title><source>JAMA</source><year>2021</year><volume>326</volume><fpage>2161</fpage><lpage>2171</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.20714</pub-id><pub-id pub-id-type="pmid">34874419</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Ospina-Tasc&#x000f3;n GA, Calder&#x000f3;n-Tapia LE, Garc&#x000ed;a AF, Zarama V, G&#x000f3;mez-&#x000c1;lvarez F, &#x000c1;lvarez-Saa T, et al. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: a randomized clinical trial. JAMA. 2021;326:2161&#x02013;71.<pub-id pub-id-type="pmid">34874419</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Grieco</surname><given-names>DL</given-names></name><name><surname>Menga</surname><given-names>LS</given-names></name><name><surname>Cesarano</surname><given-names>M</given-names></name><name><surname>Ros&#x000e0;</surname><given-names>T</given-names></name><name><surname>Spadaro</surname><given-names>S</given-names></name><name><surname>Bitondo</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure: the HENIVOT randomized clinical trial</article-title><source>JAMA</source><year>2021</year><volume>325</volume><fpage>1731</fpage><lpage>1743</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.4682</pub-id><pub-id pub-id-type="pmid">33764378</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Grieco DL, Menga LS, Cesarano M, Ros&#x000e0; T, Spadaro S, Bitondo MM, et al. Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure: the HENIVOT randomized clinical trial. JAMA. 2021;325:1731&#x02013;43.<pub-id pub-id-type="pmid">33764378</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Parshall</surname><given-names>MB</given-names></name><name><surname>Schwartzstein</surname><given-names>RM</given-names></name><name><surname>Adams</surname><given-names>L</given-names></name><name><surname>Banzett</surname><given-names>RB</given-names></name><name><surname>Manning</surname><given-names>HL</given-names></name><name><surname>Bourbeau</surname><given-names>J</given-names></name><etal/></person-group><article-title>An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea</article-title><source>Am J Respir Crit Care Med</source><year>2012</year><volume>185</volume><fpage>435</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1164/rccm.201111-2042ST</pub-id><pub-id pub-id-type="pmid">22336677</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185:435&#x02013;52.<pub-id pub-id-type="pmid">22336677</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Frat</surname><given-names>J-P</given-names></name><name><surname>Ragot</surname><given-names>S</given-names></name><name><surname>Girault</surname><given-names>C</given-names></name><name><surname>Perbet</surname><given-names>S</given-names></name><name><surname>Prat</surname><given-names>G</given-names></name><name><surname>Boulain</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trial</article-title><source>Lancet Respir Med</source><year>2016</year><volume>4</volume><fpage>646</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(16)30093-5</pub-id><pub-id pub-id-type="pmid">27245914</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Frat J-P, Ragot S, Girault C, Perbet S, Prat G, Boulain T, et al. Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trial. Lancet Respir Med. 2016;4:646&#x02013;52.<pub-id pub-id-type="pmid">27245914</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Barr</surname><given-names>J</given-names></name><name><surname>Fraser</surname><given-names>GL</given-names></name><name><surname>Puntillo</surname><given-names>K</given-names></name><name><surname>Ely</surname><given-names>EW</given-names></name><name><surname>G&#x000e9;linas</surname><given-names>C</given-names></name><name><surname>Dasta</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit</article-title><source>Crit Care Med</source><year>2013</year><volume>41</volume><fpage>263</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3182783b72</pub-id><pub-id pub-id-type="pmid">23269131</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Barr J, Fraser GL, Puntillo K, Ely EW, G&#x000e9;linas C, Dasta JF, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41:263&#x02013;306.<pub-id pub-id-type="pmid">23269131</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Fine</surname><given-names>JP</given-names></name><name><surname>Gray</surname><given-names>RJ</given-names></name></person-group><article-title>A proportional hazards model for the subdistribution of a competing risk</article-title><source>J Am Stat Assoc</source><year>1999</year><volume>94</volume><fpage>496</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1080/01621459.1999.10474144</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496&#x02013;509.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data: Kalbfleisch/The statistical [Internet]. Wiley, Hoboken, NJ, USA; 2002 [cited 2022 Mar 1]. 10.1002/9781118032985.</mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>RJ</given-names></name></person-group><article-title>A class of $K$-sample tests for comparing the cumulative incidence of a competing risk</article-title><source>Ann Stat</source><year>1988</year><pub-id pub-id-type="doi">10.1214/aos/1176350951.full</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Gray RJ. A class of $K$-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988. 10.1214/aos/1176350951.full.</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Bott</surname><given-names>J</given-names></name><name><surname>Carroll</surname><given-names>MP</given-names></name><name><surname>Conway</surname><given-names>JH</given-names></name><name><surname>Keilty</surname><given-names>SE</given-names></name><name><surname>Ward</surname><given-names>EM</given-names></name><name><surname>Brown</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease</article-title><source>Lancet Lond Engl</source><year>1993</year><volume>341</volume><fpage>1555</fpage><lpage>1557</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(93)90696-E</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Bott J, Carroll MP, Conway JH, Keilty SE, Ward EM, Brown AM, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet Lond Engl. 1993;341:1555&#x02013;7.</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>N</given-names></name><name><surname>Meyer</surname><given-names>TJ</given-names></name><name><surname>Meharg</surname><given-names>J</given-names></name><name><surname>Cece</surname><given-names>RD</given-names></name><name><surname>Hill</surname><given-names>NS</given-names></name></person-group><article-title>Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure</article-title><source>Am J Respir Crit Care Med</source><year>1995</year><volume>151</volume><fpage>1799</fpage><lpage>1806</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.151.6.7767523</pub-id><pub-id pub-id-type="pmid">7767523</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Kramer N, Meyer TJ, Meharg J, Cece RD, Hill NS. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med. 1995;151:1799&#x02013;806.<pub-id pub-id-type="pmid">7767523</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Jay</surname><given-names>GD</given-names></name><name><surname>Woolard</surname><given-names>RH</given-names></name><name><surname>Hipona</surname><given-names>RA</given-names></name><name><surname>Connolly</surname><given-names>EM</given-names></name><name><surname>Cimini</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Randomized, prospective trial of bilevel versus continuous positive airway pressure in acute pulmonary edema</article-title><source>Crit Care Med</source><year>1997</year><volume>25</volume><fpage>620</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1097/00003246-199704000-00011</pub-id><pub-id pub-id-type="pmid">9142026</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Mehta S, Jay GD, Woolard RH, Hipona RA, Connolly EM, Cimini DM, et al. Randomized, prospective trial of bilevel versus continuous positive airway pressure in acute pulmonary edema. Crit Care Med. 1997;25:620&#x02013;8.<pub-id pub-id-type="pmid">9142026</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Liesching</surname><given-names>T</given-names></name><name><surname>Nelson</surname><given-names>DL</given-names></name><name><surname>Cormier</surname><given-names>KL</given-names></name><name><surname>Sucov</surname><given-names>A</given-names></name><name><surname>Short</surname><given-names>K</given-names></name><name><surname>Warburton</surname><given-names>R</given-names></name><etal/></person-group><article-title>Randomized trial of bilevel versus continuous positive airway pressure for acute pulmonary edema</article-title><source>J Emerg Med</source><year>2014</year><volume>46</volume><fpage>130</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.jemermed.2013.08.015</pub-id><pub-id pub-id-type="pmid">24071031</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Liesching T, Nelson DL, Cormier KL, Sucov A, Short K, Warburton R, et al. Randomized trial of bilevel versus continuous positive airway pressure for acute pulmonary edema. J Emerg Med. 2014;46:130&#x02013;40.<pub-id pub-id-type="pmid">24071031</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Nava</surname><given-names>S</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Esquinas</surname><given-names>A</given-names></name><name><surname>Scala</surname><given-names>R</given-names></name><name><surname>Groff</surname><given-names>P</given-names></name><name><surname>Cosentini</surname><given-names>R</given-names></name><etal/></person-group><article-title>Palliative use of non-invasive ventilation in end-of-life patients with solid tumours: a randomised feasibility trial</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><fpage>219</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70009-3</pub-id><pub-id pub-id-type="pmid">23406914</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Nava S, Ferrer M, Esquinas A, Scala R, Groff P, Cosentini R, et al. Palliative use of non-invasive ventilation in end-of-life patients with solid tumours: a randomised feasibility trial. Lancet Oncol. 2013;14:219&#x02013;27.<pub-id pub-id-type="pmid">23406914</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Kocks</surname><given-names>JWH</given-names></name><name><surname>van den Berg</surname><given-names>JWK</given-names></name><name><surname>Kerstjens</surname><given-names>HAM</given-names></name><name><surname>Uil</surname><given-names>SM</given-names></name><name><surname>Vonk</surname><given-names>JM</given-names></name><name><surname>de Jong</surname><given-names>YP</given-names></name><etal/></person-group><article-title>Day-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary disease</article-title><source>Int J Chronic Obstr Pulm Dis</source><year>2013</year><volume>8</volume><fpage>273</fpage><lpage>286</lpage></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Kocks JWH, van den Berg JWK, Kerstjens HAM, Uil SM, Vonk JM, de Jong YP, et al. Day-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary disease. Int J Chronic Obstr Pulm Dis. 2013;8:273&#x02013;86.</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Tulaimat</surname><given-names>A</given-names></name><name><surname>Gueret</surname><given-names>RM</given-names></name><name><surname>Wisniewski</surname><given-names>MF</given-names></name><name><surname>Samuel</surname><given-names>J</given-names></name></person-group><article-title>Association between rating of respiratory distress and vital signs, severity of illness, intubation, and mortality in acutely ill subjects</article-title><source>Respir Care</source><year>2014</year><volume>59</volume><fpage>1338</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.4187/respcare.02650</pub-id><pub-id pub-id-type="pmid">24847098</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Tulaimat A, Gueret RM, Wisniewski MF, Samuel J. Association between rating of respiratory distress and vital signs, severity of illness, intubation, and mortality in acutely ill subjects. Respir Care. 2014;59:1338&#x02013;44.<pub-id pub-id-type="pmid">24847098</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Pesola</surname><given-names>GR</given-names></name><name><surname>Ahsan</surname><given-names>H</given-names></name></person-group><article-title>Dyspnea as an independent predictor of mortality</article-title><source>Clin Respir J</source><year>2016</year><volume>10</volume><fpage>142</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1111/crj.12191</pub-id><pub-id pub-id-type="pmid">25070878</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Pesola GR, Ahsan H. Dyspnea as an independent predictor of mortality. Clin Respir J. 2016;10:142&#x02013;52.<pub-id pub-id-type="pmid">25070878</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000f8;tker</surname><given-names>MT</given-names></name><name><surname>Stengaard</surname><given-names>C</given-names></name><name><surname>Andersen</surname><given-names>MS</given-names></name><name><surname>S&#x000f8;ndergaard</surname><given-names>HM</given-names></name><name><surname>Dodt</surname><given-names>KK</given-names></name><name><surname>Niemann</surname><given-names>T</given-names></name><etal/></person-group><article-title>Dyspnea, a high-risk symptom in patients suspected of myocardial infarction in the ambulance? A population-based follow-up study</article-title><source>Scand J Trauma Resusc Emerg Med</source><year>2016</year><volume>24</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/s13049-016-0204-9</pub-id><pub-id pub-id-type="pmid">26872739</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">B&#x000f8;tker MT, Stengaard C, Andersen MS, S&#x000f8;ndergaard HM, Dodt KK, Niemann T, et al. Dyspnea, a high-risk symptom in patients suspected of myocardial infarction in the ambulance? A population-based follow-up study. Scand J Trauma Resusc Emerg Med. 2016;24:15.<pub-id pub-id-type="pmid">26872739</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchberger</surname><given-names>I</given-names></name><name><surname>Heier</surname><given-names>M</given-names></name><name><surname>Kuch</surname><given-names>B</given-names></name><name><surname>von Scheidt</surname><given-names>W</given-names></name><name><surname>Meisinger</surname><given-names>C</given-names></name></person-group><article-title>Presenting symptoms of myocardial infarction predict short- and long-term mortality: the MONICA/KORA Myocardial Infarction Registry</article-title><source>Am Heart J</source><year>2012</year><volume>164</volume><fpage>856</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2012.06.026</pub-id><pub-id pub-id-type="pmid">23194485</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Kirchberger I, Heier M, Kuch B, von Scheidt W, Meisinger C. Presenting symptoms of myocardial infarction predict short- and long-term mortality: the MONICA/KORA Myocardial Infarction Registry. Am Heart J. 2012;164:856&#x02013;61.<pub-id pub-id-type="pmid">23194485</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Steer</surname><given-names>J</given-names></name><name><surname>Norman</surname><given-names>EM</given-names></name><name><surname>Afolabi</surname><given-names>OA</given-names></name><name><surname>Gibson</surname><given-names>GJ</given-names></name><name><surname>Bourke</surname><given-names>SC</given-names></name></person-group><article-title>Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD</article-title><source>Thorax</source><year>2012</year><volume>67</volume><fpage>117</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2011-200332</pub-id><pub-id pub-id-type="pmid">21896712</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Steer J, Norman EM, Afolabi OA, Gibson GJ, Bourke SC. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax. 2012;67:117&#x02013;21.<pub-id pub-id-type="pmid">21896712</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>M</given-names></name><name><surname>Kitzman</surname><given-names>DW</given-names></name><name><surname>Matsushita</surname><given-names>K</given-names></name><name><surname>Loehr</surname><given-names>L</given-names></name><name><surname>Sueta</surname><given-names>CA</given-names></name><name><surname>Shah</surname><given-names>AM</given-names></name></person-group><article-title>Prognostic importance of dyspnea for cardiovascular outcomes and mortality in persons without prevalent cardiopulmonary disease: the atherosclerosis risk in communities study</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><fpage>e0165111</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0165111</pub-id><pub-id pub-id-type="pmid">27780208</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Santos M, Kitzman DW, Matsushita K, Loehr L, Sueta CA, Shah AM. Prognostic importance of dyspnea for cardiovascular outcomes and mortality in persons without prevalent cardiopulmonary disease: the atherosclerosis risk in communities study. PLoS ONE. 2016;11: e0165111.<pub-id pub-id-type="pmid">27780208</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Frostad</surname><given-names>A</given-names></name><name><surname>S&#x000f8;yseth</surname><given-names>V</given-names></name><name><surname>Andersen</surname><given-names>A</given-names></name><name><surname>Gulsvik</surname><given-names>A</given-names></name></person-group><article-title>Respiratory symptoms as predictors of all-cause mortality in an urban community: a 30-year follow-up</article-title><source>J Intern Med</source><year>2006</year><volume>259</volume><fpage>520</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2796.2006.01631.x</pub-id><pub-id pub-id-type="pmid">16629856</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Frostad A, S&#x000f8;yseth V, Andersen A, Gulsvik A. Respiratory symptoms as predictors of all-cause mortality in an urban community: a 30-year follow-up. J Intern Med. 2006;259:520&#x02013;9.<pub-id pub-id-type="pmid">16629856</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>JP</given-names></name><name><surname>Dechen</surname><given-names>T</given-names></name><name><surname>Schwartzstein</surname><given-names>RM</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>C</given-names></name><name><surname>Baker</surname><given-names>K</given-names></name><name><surname>Banzett</surname><given-names>RB</given-names></name></person-group><article-title>Association of dyspnea, mortality, and resource use in hospitalised patients</article-title><source>Eur Respir J</source><year>2021</year><volume>58</volume><issue>3</issue><fpage>1902107</fpage><pub-id pub-id-type="doi">10.1183/13993003.02107-2019</pub-id><pub-id pub-id-type="pmid">33653806</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Stevens JP, Dechen T, Schwartzstein RM, O&#x02019;Donnell C, Baker K, Banzett RB. Association of dyspnea, mortality, and resource use in hospitalised patients. Eur Respir J. 2021;58(3):1902107.<pub-id pub-id-type="pmid">33653806</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Dupuis-Lozeron</surname><given-names>E</given-names></name><name><surname>Soccal</surname><given-names>PM</given-names></name><name><surname>Janssens</surname><given-names>J-P</given-names></name><name><surname>Similowski</surname><given-names>T</given-names></name><name><surname>Adler</surname><given-names>D</given-names></name></person-group><article-title>Severe dyspnea is an independent predictor of readmission or death in COPD patients surviving acute hypercapnic respiratory failure in the ICU</article-title><source>Front Med</source><year>2018</year><volume>5</volume><fpage>163</fpage><pub-id pub-id-type="doi">10.3389/fmed.2018.00163</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Dupuis-Lozeron E, Soccal PM, Janssens J-P, Similowski T, Adler D. Severe dyspnea is an independent predictor of readmission or death in COPD patients surviving acute hypercapnic respiratory failure in the ICU. Front Med. 2018;5:163.</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Decav&#x000e8;le</surname><given-names>M</given-names></name><name><surname>Similowski</surname><given-names>T</given-names></name></person-group><article-title>Dyspnoea upon hospital admission: listen to the bird of ill omen!</article-title><source>Eur Respir J</source><year>2021</year><volume>58</volume><fpage>2100988</fpage><pub-id pub-id-type="doi">10.1183/13993003.00988-2021</pub-id><pub-id pub-id-type="pmid">34475114</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Decav&#x000e8;le M, Similowski T. Dyspnoea upon hospital admission: listen to the bird of ill omen! Eur Respir J. 2021;58:2100988.<pub-id pub-id-type="pmid">34475114</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Puntillo</surname><given-names>KA</given-names></name><name><surname>Max</surname><given-names>A</given-names></name><name><surname>Timsit</surname><given-names>J-F</given-names></name><name><surname>Vignoud</surname><given-names>L</given-names></name><name><surname>Chanques</surname><given-names>G</given-names></name><name><surname>Robleda</surname><given-names>G</given-names></name><etal/></person-group><article-title>Determinants of procedural pain intensity in the intensive care unit. The Europain&#x000ae; study</article-title><source>Am J Respir Crit Care Med</source><year>2014</year><volume>189</volume><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1164/rccm.201306-1174OC</pub-id><pub-id pub-id-type="pmid">24262016</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Puntillo KA, Max A, Timsit J-F, Vignoud L, Chanques G, Robleda G, et al. Determinants of procedural pain intensity in the intensive care unit. The Europain&#x000ae; study. Am J Respir Crit Care Med. 2014;189:39&#x02013;47.<pub-id pub-id-type="pmid">24262016</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Demoule</surname><given-names>A</given-names></name><name><surname>Polito</surname><given-names>A</given-names></name><name><surname>Porchet</surname><given-names>R</given-names></name><name><surname>Aboab</surname><given-names>J</given-names></name><name><surname>Siami</surname><given-names>S</given-names></name><etal/></person-group><article-title>Dyspnea in mechanically ventilated critically ill patients</article-title><source>Crit Care Med</source><year>2011</year><volume>39</volume><fpage>2059</fpage><lpage>2065</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e31821e8779</pub-id><pub-id pub-id-type="pmid">21572329</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Schmidt M, Demoule A, Polito A, Porchet R, Aboab J, Siami S, et al. Dyspnea in mechanically ventilated critically ill patients. Crit Care Med. 2011;39:2059&#x02013;65.<pub-id pub-id-type="pmid">21572329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>JP</given-names></name><name><surname>Sheridan</surname><given-names>AR</given-names></name><name><surname>Bernstein</surname><given-names>HB</given-names></name><name><surname>Baker</surname><given-names>K</given-names></name><name><surname>Lansing</surname><given-names>RW</given-names></name><name><surname>Schwartzstein</surname><given-names>RM</given-names></name><etal/></person-group><article-title>A multidimensional profile of dyspnea in hospitalized patients</article-title><source>Chest</source><year>2019</year><volume>156</volume><fpage>507</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2019.04.128</pub-id><pub-id pub-id-type="pmid">31128117</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Stevens JP, Sheridan AR, Bernstein HB, Baker K, Lansing RW, Schwartzstein RM, et al. A multidimensional profile of dyspnea in hospitalized patients. Chest. 2019;156:507&#x02013;17.<pub-id pub-id-type="pmid">31128117</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Rotondi</surname><given-names>AJ</given-names></name><name><surname>Chelluri</surname><given-names>L</given-names></name><name><surname>Sirio</surname><given-names>C</given-names></name><name><surname>Mendelsohn</surname><given-names>A</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Belle</surname><given-names>S</given-names></name><etal/></person-group><article-title>Patients&#x02019; recollections of stressful experiences while receiving prolonged mechanical ventilation in an intensive care unit</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>746</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1097/00003246-200204000-00004</pub-id><pub-id pub-id-type="pmid">11940739</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Rotondi AJ, Chelluri L, Sirio C, Mendelsohn A, Schulz R, Belle S, et al. Patients&#x02019; recollections of stressful experiences while receiving prolonged mechanical ventilation in an intensive care unit. Crit Care Med. 2002;30:746&#x02013;52.<pub-id pub-id-type="pmid">11940739</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>de Miranda</surname><given-names>S</given-names></name><name><surname>Pochard</surname><given-names>F</given-names></name><name><surname>Chaize</surname><given-names>M</given-names></name><name><surname>Megarbane</surname><given-names>B</given-names></name><name><surname>Cuvelier</surname><given-names>A</given-names></name><name><surname>Bele</surname><given-names>N</given-names></name><etal/></person-group><article-title>Postintensive care unit psychological burden in patients with chronic obstructive pulmonary disease and informal caregivers: a multicenter study</article-title><source>Crit Care Med</source><year>2011</year><volume>39</volume><fpage>112</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181feb824</pub-id><pub-id pub-id-type="pmid">21037472</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">de Miranda S, Pochard F, Chaize M, Megarbane B, Cuvelier A, Bele N, et al. Postintensive care unit psychological burden in patients with chronic obstructive pulmonary disease and informal caregivers: a multicenter study. Crit Care Med. 2011;39:112&#x02013;8.<pub-id pub-id-type="pmid">21037472</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Demoule</surname><given-names>A</given-names></name><name><surname>Hajage</surname><given-names>D</given-names></name><name><surname>Messika</surname><given-names>J</given-names></name><name><surname>Jaber</surname><given-names>S</given-names></name><name><surname>Diallo</surname><given-names>H</given-names></name><name><surname>Coutrot</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevalence, intensity, and clinical impact of dyspnea in critically ill patients receiving invasive ventilation</article-title><source>Am J Respir Crit Care Med</source><year>2022</year><volume>205</volume><fpage>917</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1164/rccm.202108-1857OC</pub-id><pub-id pub-id-type="pmid">35061577</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Demoule A, Hajage D, Messika J, Jaber S, Diallo H, Coutrot M, et al. Prevalence, intensity, and clinical impact of dyspnea in critically ill patients receiving invasive ventilation. Am J Respir Crit Care Med. 2022;205:917&#x02013;26.<pub-id pub-id-type="pmid">35061577</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Currow</surname><given-names>DC</given-names></name><name><surname>Abernethy</surname><given-names>AP</given-names></name><name><surname>Ko</surname><given-names>DN</given-names></name></person-group><article-title>The active identification and management of chronic refractory breathlessness is a human right</article-title><source>Thorax</source><year>2014</year><volume>69</volume><fpage>393</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2013-204701</pub-id><pub-id pub-id-type="pmid">24212892</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Currow DC, Abernethy AP, Ko DN. The active identification and management of chronic refractory breathlessness is a human right. Thorax. 2014;69:393&#x02013;4.<pub-id pub-id-type="pmid">24212892</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Ba&#x0015f;o&#x0011f;lu</surname><given-names>M</given-names></name></person-group><article-title>Effective management of breathlessness: a review of potential human rights issues</article-title><source>Eur Respir J</source><year>2017</year><volume>49</volume><fpage>1602099</fpage><pub-id pub-id-type="doi">10.1183/13993003.02099-2016</pub-id><pub-id pub-id-type="pmid">28546267</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Ba&#x0015f;o&#x0011f;lu M. Effective management of breathlessness: a review of potential human rights issues. Eur Respir J. 2017;49:1602099.<pub-id pub-id-type="pmid">28546267</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Gentzler</surname><given-names>ER</given-names></name><name><surname>Derry</surname><given-names>H</given-names></name><name><surname>Ouyang</surname><given-names>DJ</given-names></name><name><surname>Lief</surname><given-names>L</given-names></name><name><surname>Berlin</surname><given-names>DA</given-names></name><name><surname>Xu</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Underdetection and undertreatment of dyspnea in critically ill patients</article-title><source>Am J Respir Crit Care Med</source><year>2019</year><volume>199</volume><fpage>1377</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1164/rccm.201805-0996OC</pub-id><pub-id pub-id-type="pmid">30485121</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Gentzler ER, Derry H, Ouyang DJ, Lief L, Berlin DA, Xu CJ, et al. Underdetection and undertreatment of dyspnea in critically ill patients. Am J Respir Crit Care Med. 2019;199:1377&#x02013;84.<pub-id pub-id-type="pmid">30485121</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>